

# 1 Genetic inactivation of zinc transporter SLC39A5 improves 2 liver function and hyperglycemia in obesogenic settings

3  
4 Shek Man Chim<sup>1</sup>, Kristen Howell<sup>1</sup>, John Dronzek<sup>1</sup>, Weizhen Wu<sup>1</sup>, Cristopher Van Hout<sup>1</sup>,  
5 Manuel Allen Revez Ferreira<sup>1</sup>, Bin Ye<sup>1</sup>, Alexander Li<sup>1</sup>, Susannah Brydges<sup>2</sup>, Vinayagam  
6 Arunachalam<sup>1</sup>, Anthony Marcketta<sup>1</sup>, Adam E Locke<sup>1</sup>, Jonas Bovijn<sup>1</sup>, Niek Verweij<sup>1</sup>,  
7 Tanima De<sup>1</sup>, Luca Lotta<sup>1</sup>, Lyndon Mitnau<sup>1</sup>, Michelle G. LeBlanc<sup>1</sup>, Regeneron Genetics  
8 Center<sup>1</sup>, DiscovEHR collaboration<sup>3</sup>, David Carey<sup>3</sup>, Olle Melander<sup>4</sup>, Alan Shuldiner<sup>1</sup>, Katia  
9 Karalis<sup>1</sup>, Aris N. Economides<sup>1,2†</sup> and Harikiran Nistala<sup>1†</sup>

- 10 1. Regeneron Genetics Center, 777 Old Saw Mill River Road, Tarrytown NY  
11 2. Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown NY  
12 3. Geisinger Health System, Danville, PA  
13 4. Department of Clinical Sciences in Malmö, Lund University, Malmö, Sweden

14  
15 † **Corresponding Authors:**

16 Harikiran Nistala, Ph.D  
17 Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc.  
18 777 Old Saw Mill River Road, Tarrytown NY 10591  
19 Phone: (732) 543 6367; Email: [kiran.nistala@gmail.com](mailto:kiran.nistala@gmail.com)


20  
21 Aris N. Economides, Ph.D.  
22 Regeneron Genetics Center, Regeneron Pharmaceuticals, Inc.  
23 777 Old Saw Mill River Road, Tarrytown NY 10591  
24 Email: [aris.economides@regeneron.com](mailto:aris.economides@regeneron.com)

25  
26 **Lay summary:** Loss of the Zinc transporter SLC39A5 protects from obesity-driven  
27 hyperglycemia and liver pathology.

28  
29  
30  
31  
32  
33

34 **Graphical abstract:**

35



36

37 **Manuscript Highlights:**

- 38
- Heterozygous loss-of-function mutations in *SLC39A5* associated with elevated
- 39
- circulating zinc levels and nominal reduction in type II diabetes risk in humans.
- 40
- Loss of *Slc39a5* results in elevated circulating and hepatic zinc levels in mice.
- 41
- Mice lacking *Slc39a5* function are protected against hepatic steatosis and
- 42
- hyperglycemia resulting from diet-induced obesity or leptin-receptor deficiency and
- 43
- display reduced hepatic inflammation and fibrosis resulting from diet-induced
- 44
- NASH.
- 45
- Loss of *Slc39a5* function results in hepatic AMPK and AKT activation.
- 46
- *SLC39A5* is a potential therapeutic target for fatty liver disease and type II
- 47
- diabetes.

48

49

## 50 **Abstract**

51 Recent studies have revealed a role for zinc in insulin secretion and glucose homeostasis.  
52 Randomized placebo-controlled zinc supplementation trials have demonstrated improved  
53 glycemic traits in patients with type II diabetes (T2D). Moreover, rare loss-of-function  
54 variants in the zinc efflux transporter *SLC30A8* reduce T2D risk. Despite this accumulated  
55 evidence, mechanistic understanding of how zinc influences systemic glucose  
56 homeostasis and consequently T2D risk remains unclear. To further explore the  
57 relationship between zinc and metabolic traits, we searched the exome database of the  
58 Regeneron Genetics Center-Geisinger Health System DiscovEHR cohort for genes that  
59 regulate zinc levels and associate with changes in metabolic traits. We then explored our  
60 main finding using *in vitro* and *in vivo* models. We identified rare loss-of-function (LOF)  
61 variants (MAF<1%) in *Solute Carrier Family 39, Member 5 (SLC39A5)* associated with  
62 increased circulating zinc ( $p=4.9 \times 10^{-4}$ ). Trans-ancestry meta-analysis across four studies  
63 exhibited nominal association of *SLC39A5* LOF variants with decreased T2D risk. To  
64 explore the mechanisms underlying these associations, we generated mice lacking  
65 *Slc39a5*. *Slc39a5*<sup>-/-</sup> mice display improved liver function and reduced hyperglycemia  
66 when challenged with congenital or diet-induced obesity. These improvements result from  
67 elevated hepatic zinc levels and concomitant activation of hepatic AMPK and AKT  
68 signaling, in part due to zinc mediated inhibition of hepatic protein phosphatase activity.  
69 Furthermore, under conditions of diet-induced non-alcoholic steatohepatitis (NASH),  
70 *Slc39a5*<sup>-/-</sup> mice display significantly attenuated fibrosis and inflammation. Taken together,  
71 these results suggest *SLC39A5* as a potential therapeutic target for non-alcoholic fatty  
72 liver disease (NAFLD) due to metabolic derangements including T2D.

73

74 **Introduction**

75 Zinc ( $Zn^{2+}$ ) is an essential trace element with established roles in enzyme  
76 biochemistry and other biological processes. Hence, robust homeostatic mechanisms  
77 have evolved to maintain physiological levels of zinc and coordinate spatiotemporal  
78 demands across various tissues(1). Metal transporter proteins encoded by solute carrier  
79 (SLC) gene families SLC30 (zinc transporter, ZnT) and SLC39 (Zrt- and Irt-like protein,  
80 ZIP) facilitate zinc homeostasis by mediating cellular  $Zn^{2+}$  efflux and uptake  
81 respectively(2).

82 Converging lines of evidence have shown that zinc plays a crucial role in insulin  
83 secretion and glucose metabolism. For example, increasing zinc intake improves  
84 glycemic control in prediabetics and patients with T2D(3). Furthermore, loss-of-function  
85 (LOF) variation in *SLC30A8* (encoding ZnT8, a pancreatic islet zinc transporter) in  
86 humans associates with reduced glucose levels and a 65% reduction in T2D risk resulting  
87 from enhanced insulin responsiveness to glucose combined with increased pro-insulin  
88 processing(4, 5). To further explore mechanisms underlying the T2D-protective role of  
89 zinc and identify additional genetic determinants influencing systemic zinc homeostasis,  
90 we tested loss-of-function variation in zinc transporters for association with circulating  
91 zinc and T2D risk and identified rare putative LOF (pLOF) variants (MAF<1%) in  
92 *SLC39A5* associated with elevated circulating zinc ( $p=4.9 \times 10^{-4}$ ). We demonstrate that the  
93 identified pLOF variants encode non-functional *SLC39A5* proteins. In mice, loss of  
94 *Slc39a5* results in elevated hepatic zinc, lower glucose levels, and has protective effects  
95 in models of congenital and diet-induced obesity. These effects appear to be mediated  
96 by the activation of hepatic AMPK and AKT signaling, thereby uncovering a mechanistic  
97 basis for zinc induced liver protection and indicating that *SLC39A5* inhibition may hold  
98 therapeutic potential in NAFLD and T2D.

99

100

101 **Results**

102 **Rare loss-of-function variants in *SLC39A5* associate with elevated serum zinc and**  
103 **protection from type II diabetes**

104 Using exome sequence data from participants of European ancestry in the  
105 Regeneron Genetics Center-Geisinger Health System DiscovEHR study, we identified  
106 rare pLOF variants (MAF<1%) in *SLC39A5* associated with increased circulating zinc  
107 levels in heterozygous carriers ( $p=4.9 \times 10^{-4}$ ; Fig. 1A). We also tested rare LOF variants in  
108 *SLC39A5* for association with T2D in a multi-ethnic meta-analysis of four studies (UK  
109 Biobank, DiscovEHR, Mount Sinai's BioMe study, and Malmö Diet and Cancer Study),  
110 totaling >62,000 cases and >518,000 controls, and found them to be nominally associated  
111 with protection from T2D (OR 0.82, 95%CI 0.68-0.99,  $p=3.7 \times 10^{-2}$ , Fig. 1B). Using serum  
112 call back analyses, we confirmed that circulating zinc levels in *SLC39A5* heterozygous  
113 loss of function carriers are elevated by 12% as compared to age, sex, BMI-matched  
114 reference controls ( $p=0.0024$ ; Fig. 1C). Analyses of insulin production (proinsulin/insulin),  
115 insulin clearance (insulin/c-peptide ratio) and blood glucose demonstrated no differences  
116 based on genotype (Fig. 1D-I and Suppl. Table 1). These results, in conjunction with lack  
117 of *SLC39A5* expression in pancreatic  $\beta$ -cells(6, 7), suggest that *SLC39A5* does not  
118 influence pancreatic  $\beta$ -cell development or function.

119 To test whether the pLOF variants result in loss of protein function, we first  
120 examined their expression and cellular localization by immunofluorescence and flow  
121 cytometry. In these analyses we included several observed pLOF variants:  
122 p.Y47\*(c.141C>G), p.R311\*(c.931C>T), and p.R322\*(c.964C>T). Bicistronic (IRES-  
123 DsRED) mammalian expression constructs encoding untagged wild-type or *SLC39A5*  
124 mutants (Y47\*, R311\*, R322\*) were transfected into HEK293 cells (Fig. S1A-E).  
125 Consistent with previous reports(8), flow cytometry and immunofluorescence analyses at  
126 steady state demonstrated that wild-type *SLC39A5* localized to the cell surface (Fig. S1A  
127 and B). In contrast, localization of variants Y47\*, R311\*, R322\* to the cell surface was  
128 reduced by ~91%, 98% and 99% respectively (Fig. S1D). To assess the zinc transport  
129 function of these variants, we leveraged a zinc-dependent transactivation assay using a  
130 metal regulatory element (MRE) responsive luciferase reporter. Wild-type *SLC39A5*  
131 resulted in dose-dependent activation of the reporter to  $Zn^{2+}$  (an effect that was  
132 attenuated by zinc chelator N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine) (Fig.  
133 S1C), whereas variants Y47\*, R311\*, R322\* failed to mediate a response (Fig. S1D and  
134 E). Therefore, variants Y47\*, R311\*, R322\* encode non-functional proteins. Their

135 association with elevated serum zinc levels in the corresponding carriers is consistent  
136 with the proposed role of SLC39A5 in maintaining systemic zinc homeostasis by  
137 facilitating efflux of excess serosal zinc into the gut lumen(8).

### 138 ***Slc39a5* homozygous-null mice display elevated serum and tissue zinc**

139 To investigate the role of *Slc39a5* in glucose homeostasis *in vivo*, we generated  
140 *Slc39a5*-null mice (Fig. S2A). The resulting *Slc39a5*<sup>-/-</sup> mice completely lacked *Slc39a5*  
141 transcript and protein in their duodenum and liver (Fig. S2B and C), two tissues with  
142 documented expression of SLC39A5(8). Consistent with our observations in human  
143 heterozygous LOF carriers, *Slc39a5*<sup>+/-</sup> mice had elevated circulating zinc levels (~26% in  
144 female and ~23% in male) compared to wildtype littermates. The elevation in circulating  
145 zinc was greatly accentuated in *Slc39a5*<sup>-/-</sup> mice (~280% in females and ~227% in males)  
146 compared to wild-type littermates (Fig. 2A). *Slc39a5*<sup>-/-</sup> mice displayed normal fecundity  
147 and had no overt phenotypes even at 22 months of age. Elemental analyses of major  
148 organs (in both sexes) revealed that *Slc39a5*<sup>-/-</sup> mice had significantly elevated zinc levels  
149 in the liver, bone, kidneys and brain, and lower levels in the pancreas (Fig. 2B and Suppl.  
150 Table 2). These phenotypes are consistent with previously reported *Slc39a5* knockout  
151 mouse models(9, 10). No differences in magnesium, iron, copper, cobalt or calcium were  
152 observed in liver (Fig. S11C and F). Serum chemistry analysis in adult mice (10 months,  
153 both sexes) demonstrated no differences in pancreatic amylase, renal function  
154 parameters (blood urea nitrogen, creatinine, total protein and uric acid), electrolytes  
155 (chloride, potassium and sodium), and liver enzymes (alanine aminotransferase; ALT and  
156 aspartate aminotransferase; AST) (Suppl. Table 3), suggesting that the observed  
157 changes in tissue zinc levels are physiologically inert at this age. Unlike *Slc39a5*<sup>-/-</sup> mice,  
158 *Slc39a5*<sup>+/-</sup> mice showed no changes in tissue zinc levels despite elevation in serum zinc  
159 indicating that the free exchangeable pool of serum zinc in the *Slc39a5*<sup>+/-</sup> mice is not  
160 sufficient to alter zinc balance within tissues (Suppl. Table 2). Conservation at the protein  
161 level (~83.5% identity), similar postnatal expression(11) and preserved function between  
162 mouse and human orthologs suggest that *Slc39a5*<sup>-/-</sup> mice provide a valid model to explore  
163 the observed subthreshold T2D protective effect of SLC39A5 LOF alleles in humans.

164 **Loss of *Slc39a5* results in reduced fasting blood glucose in congenital and diet-**  
165 **induced obesity models**

166 To assess whether disruption of *Slc39a5* function improves glycemic traits in mice,  
167 we challenged the *Slc39a5*<sup>-/-</sup> mice with well-established models of congenital (leptin-  
168 receptor deficiency; *Lepr*<sup>-/-</sup> mice) or diet induced obesity(12, 13). Loss of *Slc39a5* did not  
169 alter body weight in either model (Fig. 3A, E, I, M and Fig. S4A, S5A, S6A, S7A).  
170 *Slc39a5*<sup>-/-</sup>;*Lepr*<sup>-/-</sup> mice or *Slc39a5*<sup>-/-</sup> mice on high fat high fructose diet (HFFD) showed  
171 significant reduction in fasting blood glucose levels as compared to littermate controls  
172 (Fig. 3B, F, J, N and Suppl. Table 4 and 5), but not fasting insulin levels (Fig. 3C, G, K,  
173 O). However, *Slc39a5*<sup>+/-</sup> mice did not show a similar improvement in fasting blood glucose  
174 (Fig. S2D and E), indicating that loss of one copy of *Slc39a5* does not actuate a protective  
175 glucose lowering mechanism; hence, we leveraged *Slc39a5*<sup>-/-</sup> mice for further  
176 mechanistic exploration.

177 Loss of *Slc39a5* in these models demonstrated improved glucose tolerance  
178 despite no differences in insulin secretion or clearance at steady state (except female  
179 *Slc39a5*<sup>-/-</sup>; *Lepr*<sup>-/-</sup> upon fasting) as compared to littermate controls (Fig. S3, S4E-F, S5E-  
180 F, S6E-F, S7E-F, S8A-H). Consistently, loss of *Slc39a5* resulted in reduced insulin  
181 resistance in these models (Fig. 3D, H, L, P). Consistent with these observations, no  
182 differences in insulin production or clearance were observed in heterozygous carriers of  
183 *SLC39A5* LOF variants as compared to age, sex, BMI-matched reference controls (Fig.  
184 1D-H) upon serum call back analyses. Combined with the fact that single-cell  
185 transcriptomic data in both human and mouse show no expression of *SLC39A5* in  
186 pancreatic  $\beta$ -cells (6, 7, 14, 15), these results indicate that the glucose lowering effects in  
187 *Slc39a5*<sup>-/-</sup> mice appear to be independent of pancreatic  $\beta$ -cell function.

188

189 **Loss of *Slc39a5* improves liver function**

190 Given that NAFLD and T2D are concurrent comorbidities characterized by hepatic  
191 steatosis, glucose intolerance and insulin resistance(16), we explored whether loss of

192 *Slc39a5* and consequent hepatic zinc accumulation (Fig. 2B) influenced liver function in  
193 models of congenital obesity and diet-induced obesity.

194 *Slc39a5*<sup>-/-</sup>;*Lepr*<sup>-/-</sup> mice displayed significant reductions in hepatic lipid accumulation  
195 (Fig. 4A and Fig. S9A), hepatic triglyceride content (Fig. 4B and Fig. S9B), and in serum  
196 ALT and AST levels (biomarkers of liver damage) (Fig. 4C, D, Fig. S9C, D and Suppl.  
197 Table 4) compared to littermate *Lepr*<sup>-/-</sup> mice. Moreover, *Slc39a5*<sup>-/-</sup>;*Lepr*<sup>-/-</sup> mice displayed  
198 reduced NAFLD activity score (an aggregate score of macrovesicular steatosis,  
199 hepatocellular hypertrophy and inflammation) (Fig. 4E and Fig. S9E). Consistent with  
200 reduced lipid burden, expression of hepatic fatty acid synthase expression trended lower  
201 in *Slc39a5*<sup>-/-</sup>;*Lepr*<sup>-/-</sup> mice (Fig. S4B-D, S5B-D). Moreover, hepatic and serum beta-  
202 hydroxybutyrate levels were elevated in *Slc39a5*<sup>-/-</sup>;*Lepr*<sup>-/-</sup> mice as compared to *Lepr*<sup>-/-</sup>  
203 mice, indicative of elevated mitochondrial  $\beta$ -oxidation and disposal of excess hepatic lipid  
204 resulting from the leptin receptor deficiency (Fig. 4F, Fig. S8K-L, S9F).

205 Next, we examined whether loss of *Slc39a5* improves liver function in diet-induced  
206 obesity. HFFD significantly increased body weight, serum ALT and AST levels, and  
207 NAFLD activity score (Suppl. Table 5). Loss of *Slc39a5* had no considerable impact on  
208 body weight in this model but resulted in marked reductions of hepatic triglyceride content  
209 in both sexes (Fig. 4H and S9H). However, loss of *Slc39a5* resulted in sex-specific  
210 differences in most NAFLD related traits, with females benefiting more significantly  
211 compared to males, displaying significant reductions in hepatic steatosis (Fig. 4G), serum  
212 ALT (but not AST) (Fig. 4I and J), NAFLD activity score (Fig. 4K), and hepatic fatty acid  
213 synthase levels (Fig. S6B-D), and a significant elevation in hepatic and serum beta-  
214 hydroxybutyrate levels (Fig. 4L and Fig. S8J). Lastly, in contrast to what was observed in  
215 *Slc39a5*<sup>-/-</sup>;*Lepr*<sup>-/-</sup> mice, hepatic glucose-6-phosphatase levels were significantly reduced  
216 in HFFD female *Slc39a5*<sup>-/-</sup> mice (Fig. S6B-D), suggesting that reduced hepatic  
217 gluconeogenesis may contribute in part to the observed glucose lowering in these mice.

218 In HFFD male *Slc39a5*<sup>-/-</sup> mice, however, there were no improvements in serum  
219 ALT, AST and NAFLD activity score (Fig. S9I-K), despite reductions in hepatic triglyceride  
220 content (Fig. S9H). Significant elevation in hepatic and serum beta-hydroxybutyrate levels



221 and nominal reduction in hepatic fatty acid synthase levels (Fig. S7B-D, S8J and S9L)  
222 were suggestive of reduced lipid burden in HFFD male *Slc39a5*<sup>-/-</sup> mice.

223 Taken together, these studies suggest that loss of *Slc39a5* in metabolically  
224 challenged mice results in reduced hepatic lipid burden and improved hepatic insulin  
225 sensitivity, ultimately leading to improved systemic glucose homeostasis.

226

### 227 **Loss of *Slc39a5* results in activation of hepatic AMPK and AKT signaling**

228 To explore the mechanism underlying improved hepatic steatosis and glycemic  
229 traits in *Slc39a5*<sup>-/-</sup> mice we evaluated two key signaling hubs that mediate lipid metabolism  
230 and insulin sensitivity, AMPK and AKT. Activation of hepatic AMPK signaling in a diet-  
231 induced obesity model reduces hepatic steatosis and downstream inflammation and  
232 fibrosis(17), whereas activation of hepatic AKT reduces glucose production in liver(18).  
233 Hence, we evaluated phosphorylation of Thr172 in AMPK $\alpha$  subunit (p.AMPK $\alpha$ ) and  
234 Ser473 phosphorylation of AKT (p.AKT) in liver lysates from *Slc39a5*<sup>-/-</sup>; *Lepr*<sup>-/-</sup> mice and  
235 HFFD-fed *Slc39a5*<sup>-/-</sup> mice and their respective controls. Prior to evaluating p.AMPK $\alpha$  and  
236 p.AKT, we confirmed that all *Slc39a5*<sup>-/-</sup> mice used in these experiments displayed hepatic  
237 zinc accumulation (Fig. 5B and E, Fig. S10B and E) and increased expression of the zinc-  
238 responsive genes *Mt1* and *Mt2* (Fig. 5C and F, Fig. S10C and F, S11B and E, S12B and  
239 E). The p.AMPK $\alpha$  levels were elevated in both *Slc39a5*<sup>-/-</sup>; *Lepr*<sup>-/-</sup> (Fig. 5A and Fig. S10A  
240 and 11A and D) and HFFD *Slc39a5*<sup>-/-</sup> mice (Fig. 5D and Fig. S10D and S12A and D)  
241 regardless of sex as compared to controls. However, significant hepatic AKT activation  
242 was observed only in female *Slc39a5*<sup>-/-</sup>; *Lepr*<sup>-/-</sup> and HFFD *Slc39a5*<sup>-/-</sup> mice (Fig. 5A and D,  
243 Fig. S10A and D, S11A and D, S12A and D).

244 To further explore the potential role of elevated hepatic zinc in AMPK and AKT  
245 activation, we examined whether exogenous zinc activates AMPK and AKT signaling in  
246 primary human hepatocytes. Zinc activated AKT signaling in these cells in a dose  
247 dependent manner with no adverse effect on cell viability, whereas magnesium had no  
248 effect (Fig. 5G and H, Fig. S13A). Moreover, zinc activated AMPK signaling and its  
249 downstream substrates acetyl-CoA carboxylase (ACC), and liver kinase B1 (LKB1; the

250 kinase responsible for AMPK $\alpha$  Thr172 phosphorylation) (Fig. 5G and H). Time-resolved  
251 analyses of zinc-mediated activation of LKB, AMPK, and AKT indicated that zinc activates  
252 AMPK and AKT signaling acutely (within 4 hours) suggesting that zinc influences  
253 phosphorylation of these substrates independent of *de novo* protein synthesis (Fig.  
254 S13B). Similar results were obtained in the human hepatoma cell line HepG2 (Fig. S13C  
255 and D).

256 Zinc is a potent inhibitor of protein phosphatases, including protein phosphatase  
257 2A (PP2A) and protein tyrosine phosphatase-1B (PTP1B)(19, 20), both of which regulate  
258 the phosphorylation of AMPK $\alpha$ . Liver-specific ablation of *Ppp2ca* (encoding PP2A's  
259 catalytic subunit) improves glucose tolerance and insulin sensitivity in mice(21), whereas  
260 liver-specific ablation of *Ptpn1* (encoding PTP1B) improves glucose tolerance, insulin  
261 sensitivity, and lipid metabolism(22). Given that hepatic zinc is elevated in *Slc39a5*<sup>-/-</sup> mice,  
262 we evaluated hepatic phosphoserine/threonine (p.Ser/Thr) and phosphotyrosine (p.Tyr)  
263 phosphatase activity in the congenital and diet-induced obesity mice at endpoint. *Slc39a5*<sup>-/-</sup>  
264 *;**Lepr*<sup>-/-</sup> mice displayed reduced p.Ser/Thr and p.Tyr phosphatase activity compared to  
265 *Lepr*<sup>-/-</sup> littermate controls (Fig. S14A and B). Under HFFD, female *Slc39a5*<sup>-/-</sup> mice showed  
266 reduced hepatic p.Ser/Thr and p.Tyr phosphatase activity (33% and 28% respectively),  
267 and non-statistically significant reductions were also observed in male *Slc39a5*<sup>-/-</sup> mice  
268 (Fig. S14C and D). Consistent with these observations, exogenous zinc inhibited  
269 p.Ser/Thr and p.Tyr phosphatase activity in primary human hepatocytes in a dose  
270 dependent manner (Fig. S14E). These results point to zinc mediated inhibition of protein  
271 phosphatase activity as a likely mechanism underlying hepatic AMPK and AKT activation  
272 in *Slc39a5*<sup>-/-</sup> mice.

273

## 274 **Loss of *Slc39a5* reduces hepatic inflammation and fibrosis upon a NASH dietary** 275 **challenge**

276 NAFLD encompasses a continuum of liver conditions from nonalcoholic fatty liver  
277 characterized by steatosis, to nonalcoholic steatohepatitis (NASH) characterized by  
278 inflammation and fibrosis(23). The improvements in liver function and steatosis in  
279 congenital and diet-induced obesity mouse models lacking *Slc39a5*, led us to investigate

280 whether loss of *Slc39a5* protects against NASH. Diet-induced NASH significantly  
281 increased serum ALT and AST levels (Fig. 6A and B, Fig. S15A and B), body weight,  
282 fasting blood glucose (Fig. S16A, B, F, G) and liver fibrosis (Fig. 6H and I, Fig. S15H and  
283 I) in *Slc39a5*<sup>+/+</sup> mice (Suppl. Table 6). In contrast, *Slc39a5*<sup>-/-</sup> mice challenged with diet-  
284 induced NASH displayed significant reductions in serum ALT and AST levels (Fig. 6A and  
285 B, Fig. S15A and B) and fasting blood glucose (Fig. S16B and G), along with significant  
286 improvements in hepatic inflammation and fibrosis (Fig. 6E and H, Fig. S15E and H) and  
287 the expected increases in serum and hepatic zinc (Fig. S16C, D, H, I). Consistently,  
288 hepatic collagen deposition (Fig. 6G, Fig. S15G) were significantly reduced in NASH  
289 *Slc39a5*<sup>-/-</sup> mice. However, NASH *Slc39a5*<sup>-/-</sup> mice were not protected from hepatic  
290 steatosis or hepatocyte hypertrophy (Fig. 6C and D, S15C and D). NAFLD activity score  
291 and steatosis-activity-fibrosis score (sum of NAFLD activity score and fibrosis score) were  
292 significantly reduced in female NASH *Slc39a5*<sup>-/-</sup> mice, but not in their male counterparts  
293 (Fig. 6F and I, Fig. S15F and I). Nonetheless, hepatic superoxide dismutase (SOD)  
294 activity was significantly elevated in both sexes in NASH *Slc39a5*<sup>-/-</sup> mice (Fig. S16E and  
295 J), suggesting that the increase in hepatic zinc may be ameliorating the increased hepatic  
296 oxidative stress observed in NASH(23).

297 In aggregate, these studies suggest that the favorable metabolic profile in the  
298 *Slc39a5*<sup>-/-</sup> mice results from convergent hepatoprotective effects due to reduced lipotoxic  
299 and oxidative stress.

300

## 301 Discussion

302 Zinc is a required trace element for many biological processes. Hence,  
303 homeostatic mechanisms have evolved to maintain optimal zinc levels across tissues(1).  
304 This regulation is accomplished by multiple transporters encoded by the *SLC30* and  
305 *SLC39* gene families(2). Given the apparent complexity of the system, we chose to take  
306 a human genetics approach to search for zinc transporter genes associated with  
307 metabolic traits and discovered a novel association of LOF variants in *SLC39A5* with  
308 increased circulating zinc ( $p=4.9 \times 10^{-4}$ ) and a reduced risk of T2D (OR 0.82, 95%CI 0.68-  
309 0.99,  $p=3.7 \times 10^{-2}$ ).

310 To firm up this association and explore underlying molecular mechanisms, we  
311 generated mice lacking *Slc39a5*. In line with the human data, and consistent with the  
312 proposed role of *Slc39a5* as a non-redundant cell surface zinc transporter facilitating  
313 endogenous zinc excretion(8, 9, 11), there was significant zinc accumulation in *Slc39a5*  
314 <sup>-/-</sup> mice across several tissues including liver (Suppl. Table 2). However, there was no  
315 significant accumulation of zinc in tissues of *Slc39a5* heterozygous-null mice on a zinc  
316 adequate diet despite significant increases in serum zinc (~26% in females and ~23% in  
317 males; Fig. 2), suggesting that the relative increase of serum zinc in heterozygotes (albeit  
318 significant) is insufficient to increase zinc levels in tissues with substantial zinc stores  
319 such as the liver.

320 Nonetheless, given the connection with protective effects arising from  
321 heterozygous loss of *SLC39A5* in humans, we examined the effect of loss of *Slc39a5* in  
322 mice under conditions of metabolic stress, employing models of congenital or diet-  
323 induced obesity, and NASH. We demonstrate that in all three models, loss of *Slc39a5* (in  
324 homozygosis) has protective effects that arise from elevation of circulating and hepatic  
325 zinc levels. In congenital or HFFD-induced obesity, there was improvement in glycemic  
326 traits and liver function, and a reduction of steatosis, which were not accompanied by  
327 reductions in body weight or changes in insulin profile. In a model of diet-induced NASH,  
328 loss of *Slc39a5* reduced hepatic inflammation and fibrosis, but without significant changes  
329 in steatosis. Mechanistically, these protective effects result at least in part from inhibition  
330 of protein phosphatases (as result of elevated levels of zinc), and consequent increase in  
331 hepatic AMPK and AKT activation.

332 The observed protective metabolic effects appear to be extra-pancreatic in both  
333 mice and humans, as supported by several lines of evidence. Carriers of heterozygous  
334 LOF mutations in *SLC39A5* have elevated serum zinc but exhibit no differences in insulin  
335 production or clearance as compared to age, sex, and BMI-matched homozygous  
336 reference controls (Fig. 1C-E). As in humans, loss of *Slc39a5* in mice results in elevated  
337 serum zinc (Fig. 2A) without impairment in pancreatic function (Suppl. Table 3). Moreover,  
338 the observed antihyperglycemic effects in *Slc39a5*<sup>-/-</sup> mice are not driven by changes in  
339 insulin production or clearance (Fig. S4-S7). Taken together, these observations suggest  
340 that the protective metabolic changes are extra-pancreatic.

341 Furthermore, our data strongly indicates that the protective effects of loss of  
342 *Slc39a5* are actuated by elevated hepatic zinc concentrations. Several lines of evidence  
343 support this interpretation. First, metabolic challenges in the form of congenital or diet-  
344 induced obesity in mice revealed hepatic zinc deficiency (Fig. 5B, Fig. S10B) along with  
345 associated comorbidities including hepatic steatosis, increased fasting blood glucose and  
346 impaired insulin sensitivity (Fig. 3). Second, loss of *Slc39a5* in these models resulted in  
347 the accumulation of serum zinc and hepatic zinc and concomitant improvement in liver  
348 function (Fig. 4-5, Fig. S9) and systemic glucose homeostasis (Fig. 3, Fig. S3). This data  
349 are consistent with observations that zinc deficiency is associated with obesity(24) and is  
350 a biochemical hallmark of fatty liver disease in both rodents and humans(25); conversely,  
351 zinc supplementation reverses manifestations of zinc deficiency in fatty liver disease and  
352 long-term oral zinc supplementation can support liver function and prevent hepatocellular  
353 carcinoma development in patients with chronic liver diseases(26).

354 The importance of hepatic zinc in the protective effects against obesity and NASH  
355 is further supported by our findings that elevated hepatic zinc in *Slc39a5*<sup>-/-</sup> mice enhanced  
356 hepatic AMPK and hepatic AKT signaling (Fig. 5 and Fig. S10). These increases  
357 correlated with reductions in hepatic p.Ser/Thr phosphatase and p.Tyr phosphatase  
358 levels in both diet-induced and congenital obesity models (Suppl. Fig. S14A-D), and were  
359 corroborated by *in vitro* evidence (Fig. S14E-F). These findings mirror prior studies  
360 showing that zinc inhibits protein serine/threonine and tyrosine phosphatases that  
361 dephosphorylate AMPK and AKT (19, 27-31). In turn, in states of lipotoxic stress,  
362 serine/threonine phosphatases such as PP2A and PP2C inhibit AMPK resulting in a feed  
363 forward effect of the lipid overload(32, 33), whereas protein tyrosine phosphatases  
364 including PTP1B, TCPTP and PTEN have been implicated in systemic glucose  
365 homeostasis by regulating the PI3K-AKT pathway (22, 30, 34, 35).

366 Overall, our studies indicate that the favorable metabolic profile observed in the  
367 *Slc39a5*<sup>-/-</sup> mice results from the loss of endogenous zinc excretion and concomitant  
368 systemic zinc redistribution. Our study provides for the first-time genetic evidence  
369 demonstrating the protective role of zinc against hyperglycemia and unravels the  
370 mechanistic basis underlying this effect. Taken together, these observations suggest

371 SLC39A5 inhibition as a potential therapeutic avenue for T2D, and other indications  
372 where zinc supplementation alone is inadequate.

373  
374 **Materials and methods**

375 *Slc39a5*<sup>-/-</sup> and *Lepr*<sup>-/-</sup> mouse lines were created using VelociGene® technology(39).  
376 *Lepr*<sup>-/-</sup> mice were bred with *Slc39a5*<sup>-/-</sup> mice to generate *Slc39a5*<sup>-/-</sup>; *Lepr*<sup>-/-</sup>. All studies were  
377 performed in both sexes. For HFFD study, ten-week-old mice were fed HFFD diet  
378 (46kcal% Fat, 30kcal% Fructose, TestDiet 5WK9) or control diet (TestDiet 58Y2) for 30  
379 weeks. For NASH study, ten-week-old mice were fed NASH diet (40kcal% Fat, 20 kcal%  
380 Fructose and 2% Cholesterol, ResearchDiets D09100310) or control diet (ResearchDiets  
381 D09100304) for 40 weeks. All mice used in this study were housed in pathogen-free  
382 environment at Regeneron Pharmaceuticals Inc. animal research facility. Sterile water  
383 and chow were provided *ad libitum*. All experimental protocols and tissue harvesting  
384 procedures were performed with Regeneron Pharmaceuticals Inc., Institutional Animal  
385 Care and Use Committee (IACUC) approval. Data are presented as box plots with  
386 individual values. Statistical analysis was performed using one-way or two-way ANOVA,  
387 followed by post hoc Tukey's tests. Statistical significance reported when p<0.05. Sample  
388 sizes, statistical test and significance are described in each figure legend.  
389 Full Methods and any associated references are available in supplementary information.

390  
391 **List of Supplementary Materials**

392  
393 Supplementary Methods  
394 Fig S1 to S16  
395 Table S1 to S6

396  
397  
398

399 **References:**

- 400 1. M. J. Jackson, D. A. Jones, R. H. Edwards, Tissue zinc levels as an index of body zinc  
401 status. *Clin Physiol* **2**, 333-343 (1982).
- 402 2. R. E. Dempshi, The cation selectivity of the ZIP transporters. *Curr Top Membr* **69**, 221-  
403 245 (2012).
- 404 3. P. Ranasinghe, W. S. Wathurapatha, P. Galappatthy, P. Katulanda, R. Jayawardena, G. R.  
405 Constantine, Zinc supplementation in prediabetes: A randomized double-blind placebo-  
406 controlled clinical trial. *J Diabetes* **10**, 386-397 (2018).
- 407 4. J. Flannick, G. Thorleifsson, N. L. Beer, S. B. Jacobs, N. Grarup, N. P. Burt, A. Mahajan, C.  
408 Fuchsberger, G. Atzmon, R. Benediktsson, J. Blangero, D. W. Bowden, I. Brandslund, J.  
409 Brosnan, F. Burslem, J. Chambers, Y. S. Cho, C. Christensen, D. A. Douglas, R. Duggirala,  
410 Z. Dymek, Y. Farjoun, T. Fennell, P. Fontanillas, T. Forsen, S. Gabriel, B. Glaser, D. F.  
411 Gudbjartsson, C. Hanis, T. Hansen, A. B. Hreidarsson, K. Hveem, E. Ingelsson, B. Isomaa,  
412 S. Johansson, T. Jorgensen, M. E. Jorgensen, S. Kathiresan, A. Kong, J. Kooner, J. Kravic,  
413 M. Laakso, J. Y. Lee, L. Lind, C. M. Lindgren, A. Linneberg, G. Masson, T. Meitinger, K. L.  
414 Mohlke, A. Molven, A. P. Morris, S. Potluri, R. Rauramaa, R. Ribel-Madsen, A. M. Richard,  
415 T. Rolph, V. Salomaa, A. V. Segre, H. Skarstrand, V. Steinthorsdottir, H. M. Stringham, P.  
416 Sulem, E. S. Tai, Y. Y. Teo, T. Teslovich, U. Thorsteinsdottir, J. K. Trimmer, T. Tuomi, J.  
417 Tuomilehto, F. Vaziri-Sani, B. F. Voight, J. G. Wilson, M. Boehnke, M. I. McCarthy, P. R.  
418 Njolstad, O. Pedersen, T. D. C. Go, T. D. G. Consortium, L. Groop, D. R. Cox, K.  
419 Stefansson, D. Altshuler, Loss-of-function mutations in SLC30A8 protect against type 2  
420 diabetes. *Nat Genet* **46**, 357-363 (2014).
- 421 5. O. P. Dwivedi, M. Lehtovirta, B. Hastoy, V. Chandra, N. A. J. Krentz, S. Kleiner, D. Jain, A.  
422 M. Richard, F. Abaitua, N. L. Beer, A. Grotz, R. B. Prasad, O. Hansson, E. Ahlqvist, U. Krus,  
423 I. Artner, A. Suoranta, D. Gomez, A. Baras, B. Champon, A. J. Payne, D. Moralli, S. K.  
424 Thomsen, P. Kramer, I. Spiliotis, R. Ramracheya, P. Chabosseau, A. Theodoulou, R.  
425 Cheung, M. van de Bunt, J. Flannick, M. Trombetta, E. Bonora, C. B. Wolheim, L. Sarelin,  
426 R. C. Bonadonna, P. Rorsman, B. Davies, J. Brosnan, M. I. McCarthy, T. Otonkoski, J. O.  
427 Lagerstedt, G. A. Rutter, J. Gromada, A. L. Gloyn, T. Tuomi, L. Groop, Loss of ZnT8  
428 function protects against diabetes by enhanced insulin secretion. *Nat Genet* **51**, 1596-  
429 1606 (2019).
- 430 6. M. Baron, A. Veres, S. L. Wolock, A. L. Faust, R. Gaujoux, A. Vetere, J. H. Ryu, B. K.  
431 Wagner, S. S. Shen-Orr, A. M. Klein, D. A. Melton, I. Yanai, A Single-Cell Transcriptomic  
432 Map of the Human and Mouse Pancreas Reveals Inter- and Intra-cell Population  
433 Structure. *Cell Syst* **3**, 346-360 e344 (2016).
- 434 7. M. J. Muraro, G. Dharmadhikari, D. Grun, N. Groen, T. Dielen, E. Jansen, L. van Gurp, M.  
435 A. Engelse, F. Carlotti, E. J. de Koning, A. van Oudenaarden, A Single-Cell Transcriptome  
436 Atlas of the Human Pancreas. *Cell Syst* **3**, 385-394 e383 (2016).
- 437 8. F. Wang, B. E. Kim, M. J. Petris, D. J. Eide, The mammalian Zip5 protein is a zinc  
438 transporter that localizes to the basolateral surface of polarized cells. *J Biol Chem* **279**,  
439 51433-51441 (2004).

- 440 9. J. Geiser, R. C. De Lisle, G. K. Andrews, The zinc transporter Zip5 (Slc39a5) regulates  
441 intestinal zinc excretion and protects the pancreas against zinc toxicity. *PLoS One* **8**,  
442 e82149 (2013).
- 443 10. X. Wang, H. Gao, W. Wu, E. Xie, Y. Yu, X. He, J. Li, W. Zheng, X. Wang, X. Cao, Z. Meng, L.  
444 Chen, J. Min, F. Wang, The zinc transporter Slc39a5 controls glucose sensing and insulin  
445 secretion in pancreatic beta-cells via Sirt1- and Pgc-1alpha-mediated regulation of Glut2.  
446 *Protein Cell* **10**, 436-449 (2019).
- 447 11. J. Dufner-Beattie, Y. M. Kuo, J. Gitschier, G. K. Andrews, The adaptive response to  
448 dietary zinc in mice involves the differential cellular localization and zinc regulation of  
449 the zinc transporters ZIP4 and ZIP5. *J Biol Chem* **279**, 49082-49090 (2004).
- 450 12. B. W. Huang, M. T. Chiang, H. T. Yao, W. Chiang, The effect of high-fat and high-fructose  
451 diets on glucose tolerance and plasma lipid and leptin levels in rats. *Diabetes Obes*  
452 *Metab* **6**, 120-126 (2004).
- 453 13. A. J. King, The use of animal models in diabetes research. *Br J Pharmacol* **166**, 877-894  
454 (2012).
- 455 14. C. Tabula Muris, A single-cell transcriptomic atlas characterizes ageing tissues in the  
456 mouse. *Nature* **583**, 590-595 (2020).
- 457 15. Y. Xin, J. Kim, M. Ni, Y. Wei, H. Okamoto, J. Lee, C. Adler, K. Cavino, A. J. Murphy, G. D.  
458 Yancopoulos, H. C. Lin, J. Gromada, Use of the Fluidigm C1 platform for RNA sequencing  
459 of single mouse pancreatic islet cells. *Proc Natl Acad Sci U S A* **113**, 3293-3298 (2016).
- 460 16. H. Tilg, A. R. Moschen, M. Roden, NAFLD and diabetes mellitus. *Nat Rev Gastroenterol*  
461 *Hepatol* **14**, 32-42 (2017).
- 462 17. D. Garcia, K. Hellberg, A. Chaix, M. Wallace, S. Herzig, M. G. Badur, T. Lin, M. N.  
463 Shokhirev, A. F. M. Pinto, D. S. Ross, A. Saghatelian, S. Panda, L. E. Dow, C. M. Metallo, R.  
464 J. Shaw, Genetic Liver-Specific AMPK Activation Protects against Diet-Induced Obesity  
465 and NAFLD. *Cell Rep* **26**, 192-208 e196 (2019).
- 466 18. P. M. Titchenell, W. J. Quinn, M. Lu, Q. Chu, W. Lu, C. Li, H. Chen, B. R. Monks, J. Chen, J.  
467 D. Rabinowitz, M. J. Birnbaum, Direct Hepatocyte Insulin Signaling Is Required for  
468 Lipogenesis but Is Dispensable for the Suppression of Glucose Production. *Cell Metab*  
469 **23**, 1154-1166 (2016).
- 470 19. E. Bellomo, K. Birla Singh, A. Massarotti, C. Hogstrand, W. Maret, The metal face of  
471 protein tyrosine phosphatase 1B. *Coord Chem Rev* **327-328**, 70-83 (2016).
- 472 20. Y. Xiong, X. P. Jing, X. W. Zhou, X. L. Wang, Y. Yang, X. Y. Sun, M. Qiu, F. Y. Cao, Y. M. Lu,  
473 R. Liu, J. Z. Wang, Zinc induces protein phosphatase 2A inactivation and tau  
474 hyperphosphorylation through Src dependent PP2A (tyrosine 307) phosphorylation.  
475 *Neurobiol Aging* **34**, 745-756 (2013).
- 476 21. L. Xian, S. Hou, Z. Huang, A. Tang, P. Shi, Q. Wang, A. Song, S. Jiang, Z. Lin, S. Guo, X. Gao,  
477 Liver-specific deletion of Ppp2calpha enhances glucose metabolism and insulin  
478 sensitivity. *Aging (Albany NY)* **7**, 223-232 (2015).
- 479 22. M. Delibegovic, D. Zimmer, C. Kauffman, K. Rak, E. G. Hong, Y. R. Cho, J. K. Kim, B. B.  
480 Kahn, B. G. Neel, K. K. Bence, Liver-specific deletion of protein-tyrosine phosphatase 1B  
481 (PTP1B) improves metabolic syndrome and attenuates diet-induced endoplasmic  
482 reticulum stress. *Diabetes* **58**, 590-599 (2009).



- 483 23. S. L. Friedman, B. A. Neuschwander-Tetri, M. Rinella, A. J. Sanyal, Mechanisms of NAFLD  
484 development and therapeutic strategies. *Nat Med* **24**, 908-922 (2018).
- 485 24. D. N. Marreiro, M. Fisberg, S. M. Cozzolino, Zinc nutritional status in obese children and  
486 adolescents. *Biol Trace Elem Res* **86**, 107-122 (2002).
- 487 25. M. K. Mohammad, Z. Zhou, M. Cave, A. Barve, C. J. McClain, Zinc and liver disease. *Nutr*  
488 *Clin Pract* **27**, 8-20 (2012).
- 489 26. A. Hosui, E. Kimura, S. Abe, T. Tanimoto, K. Onishi, Y. Kusumoto, Y. Sueyoshi, K.  
490 Matsumoto, M. Hirao, T. Yamada, N. Hiramatsu, Long-Term Zinc Supplementation  
491 Improves Liver Function and Decreases the Risk of Developing Hepatocellular  
492 Carcinoma. *Nutrients* **10**, (2018).
- 493 27. E. Bellomo, A. Abro, C. Hogstrand, W. Maret, C. Domene, Role of Zinc and Magnesium  
494 Ions in the Modulation of Phosphoryl Transfer in Protein Tyrosine Phosphatase 1B. *J Am*  
495 *Chem Soc* **140**, 4446-4454 (2018).
- 496 28. S. Lee, G. Chanoit, R. McIntosh, D. A. Zvara, Z. Xu, Molecular mechanism underlying Akt  
497 activation in zinc-induced cardioprotection. *Am J Physiol Heart Circ Physiol* **297**, H569-  
498 575 (2009).
- 499 29. S. Liangpunsakul, M. S. Sozio, E. Shin, Z. Zhao, Y. Xu, R. A. Ross, Y. Zeng, D. W. Crabb,  
500 Inhibitory effect of ethanol on AMPK phosphorylation is mediated in part through  
501 elevated ceramide levels. *Am J Physiol Gastrointest Liver Physiol* **298**, G1004-1012  
502 (2010).
- 503 30. S. Galic, C. Hauser, B. B. Kahn, F. G. Haj, B. G. Neel, N. K. Tonks, T. Tiganis, Coordinated  
504 regulation of insulin signaling by the protein tyrosine phosphatases PTP1B and TCPTP.  
505 *Mol Cell Biol* **25**, 819-829 (2005).
- 506 31. N. Krishnan, K. F. Konidaris, G. Gasser, N. K. Tonks, A potent, selective, and orally  
507 bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and  
508 leptin signaling in animal models. *J Biol Chem* **293**, 1517-1525 (2018).
- 509 32. T. C. Chen, D. I. Benjamin, T. Kuo, R. A. Lee, M. L. Li, D. J. Mar, D. E. Costello, D. K.  
510 Nomura, J. C. Wang, The glucocorticoid-Angptl4-ceramide axis induces insulin resistance  
511 through PP2A and PKCzeta. *Sci Signal* **10**, (2017).
- 512 33. M. Y. Wang, R. H. Unger, Role of PP2C in cardiac lipid accumulation in obese rodents and  
513 its prevention by troglitazone. *Am J Physiol Endocrinol Metab* **288**, E216-221 (2005).
- 514 34. A. Pal, T. M. Barber, M. Van de Bunt, S. A. Rudge, Q. Zhang, K. L. Lachlan, N. S. Cooper,  
515 H. Linden, J. C. Levy, M. J. Wakelam, L. Walker, F. Karpe, A. L. Gloyn, PTEN mutations as  
516 a cause of constitutive insulin sensitivity and obesity. *N Engl J Med* **367**, 1002-1011  
517 (2012).
- 518 35. R. C. Tsou, K. K. Bence, The Genetics of PTPN1 and Obesity: Insights from Mouse Models  
519 of Tissue-Specific PTP1B Deficiency. *J Obes* **2012**, 926857 (2012).
- 520 36. M. Regnier, A. Polizzi, S. Smati, C. Lukowicz, A. Fougerat, Y. Lippi, E. Fouche, F. Lasserre,  
521 C. Naylies, C. Betoulieres, V. Barquissau, E. Mouisel, J. Bertrand-Michel, A. Batut, T. A.  
522 Saati, C. Canlet, M. Tremblay-Franco, S. Ellero-Simatos, D. Langin, C. Postic, W. Wahli, N.  
523 Loiseau, H. Guillou, A. Montagner, Hepatocyte-specific deletion of Pparalpha promotes  
524 NAFLD in the context of obesity. *Sci Rep* **10**, 6489 (2020).

- 525 37. J. J. Zhang, J. J. Hao, Y. R. Zhang, Y. L. Wang, M. Y. Li, H. L. Miao, X. J. Zou, B. Liang, Zinc  
526 mediates the SREBP-SCD axis to regulate lipid metabolism in *Caenorhabditis elegans*. *J*  
527 *Lipid Res* **58**, 1845-1854 (2017).
- 528 38. Y. Bai, J. G. McCoy, E. J. Levin, P. Sobrado, K. R. Rajashankar, B. G. Fox, M. Zhou, X-ray  
529 structure of a mammalian stearyl-CoA desaturase. *Nature* **524**, 252-256 (2015).
- 530 39. D. M. Valenzuela, A. J. Murphy, D. Friendewey, N. W. Gale, A. N. Economides, W.  
531 Auerbach, W. T. Poueymirou, N. C. Adams, J. Rojas, J. Yasenchak, R. Chernomorsky, M.  
532 Boucher, A. L. Elsasser, L. Esau, J. Zheng, J. A. Griffiths, X. Wang, H. Su, Y. Xue, M. G.  
533 Dominguez, I. Noguera, R. Torres, L. E. Macdonald, A. F. Stewart, T. M. DeChiara, G. D.  
534 Yancopoulos, High-throughput engineering of the mouse genome coupled with high-  
535 resolution expression analysis. *Nat Biotechnol* **21**, 652-659 (2003).

536

### 537 **Acknowledgements:**

538

539 We wish to thank individuals that consented to be part of the Regeneron Genetics  
540 Center-Geisinger Health System DiscovEHR study. We would also like to acknowledge  
541 Kristy Neiman and William Poueymirou for their assistance with mouse colony  
542 management, and Suganthi Balasubramanian for insightful comments and input at the  
543 inception of the project, and Sergio Fazio for a critical reading of our manuscript.

544

545 **Funding:** This work was supported by Regeneron Pharmaceuticals.

546

### 547 **Author contributions:**

548 H.N., A.N.E. and S.M.C. designed the study. S.M.C., K.H., J.D., W.W. and H.N.  
549 generated and analyzed the data. H.N., C.V.H., M.A.R.F., B.Y., A.L., S.B., V.A., A.M.,  
550 A.E.L., J.B., N.V., T.D., L.L., L.M., M.G.L., D.C., O.M., A.S., DiscovEHR and Regeneron  
551 Genetics Center performed the human genetics data collection and analysis. S.M.C.,  
552 K.K., A.N.E. and H.N. wrote the manuscript.

553

### 554 **Conflict of Interest Statement:**

555

556 S.M.C., K.H., W.W., M.A.R.F., B.Y., A.L., S.B., A.M., A.E.L., J.B., N.V., T.D., L.L.,  
557 L.M., M.G.L., A.S., K.K., A.N.E., are full-time employees of the Regeneron Genetics  
558 Center or Regeneron Pharmaceuticals Inc. and hold stock options/restricted stock as part  
559 of compensation.

560

561

562 **Figure legends:**

563 **Fig. 1. Rare pLOF variants in *SLC39A5* are associated with elevated serum zinc and**  
564 **nominal protection against type II diabetes (T2D).** (A) Serum zinc in carriers of  
565 *SLC39A5* pLOF variants in the discovery cohort. Controls (Ref; *SLC39A5*<sup>+/+</sup>) and  
566 heterozygous carriers of pLOF variant alleles in *SLC39A5* (Het; *SLC39A5*<sup>+/-</sup>). Subject  
567 numbers: Ref and Het respectively: n=5317 and n=15. (B) Trans-ancestry meta-analysis  
568 of association of *SLC39A5* pLOF variants with T2D. (C-I) Serum zinc and insulin profile  
569 of age, sex and BMI-matched controls in serum call back study. Subject numbers: Ref  
570 and Het respectively: n=246-253 and n=86-91, \*\*P < 0.01, unpaired t-test. Numeric data  
571 is summarized in Suppl. Table 1.

572

573 **Fig. 2. Loss of *Slc39a5* results in elevated circulating and hepatic zinc levels in**  
574 **mice.** Serum zinc (A) and hepatic zinc (B) in *Slc39a5*<sup>+/+</sup>, *Slc39a5*<sup>-/-</sup> and *Slc39a5*<sup>+/-</sup> mice at  
575 40 weeks of age, n=16-18. \*\*P < 0.01, \*\*\*P < 0.001, two-way ANOVA with post hoc  
576 Tukey's test.

577

578 **Fig. 3. Loss of *Slc39a5* improves glycemic traits in leptin-receptor deficient mice**  
579 **and in mice challenged with high fat high fructose diet (HFFD).** Female (A-D, I-L; ♀)  
580 and Male (E-H, M-P; ♂) mice. (A-H) *Slc39a5*<sup>-/-</sup>; *Lepr*<sup>-/-</sup> and corresponding control mice. (A,  
581 E) Body weight at 34 weeks. (B, F) Fasting blood glucose at 34 weeks. (C, G) Fasting  
582 insulin at 34 weeks. (D, H) Homeostatic model assessment for insulin resistance (HOMA-  
583 IR) at 34 weeks. *Slc39a5*<sup>+/+</sup> and *Slc39a5*<sup>-/-</sup> (n=5-12), *Lepr*<sup>-/-</sup> and *Slc39a5*<sup>-/-</sup>; *Lepr*<sup>-/-</sup> (n=10-  
584 15). \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, one-way ANOVA with post hoc Tukey's test. (I-P)  
585 *Slc39a5*<sup>-/-</sup> and *Slc39a5*<sup>+/+</sup> mice were fed HFFD or NC for 30 weeks. (I, M) Body weight at  
586 30 weeks. (J, N) Fasting blood glucose at 30 weeks. (K, O) Fasting insulin at 30 weeks.  
587 (L, P) HOMA-IR at 30 weeks, n=11-15. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, two-way  
588 ANOVA with post hoc Tukey's test. Numeric data is summarized in Suppl. Table 4 and 5.

589

590 **Fig. 4. Loss of *Slc39a5* improves liver function and steatosis in leptin-receptor**  
591 **deficient female mice and in female mice challenged with high fat high fructose diet**

592 **(HFFD)**. *Slc39a5*<sup>-/-</sup>;*Lepr*<sup>-/-</sup> and corresponding control mice (A-F) were sacrificed after 16  
593 hour fasting at 34 weeks of age. (G-L) *Slc39a5*<sup>-/-</sup> and *Slc39a5*<sup>+/+</sup> mice were fed HFFD or  
594 NC for 30 weeks and sacrificed after 16 hours fasting. (A, G) Representative images of  
595 livers stained with H&E. Scale bar, 200µm. (B, H) Hepatic triglyceride (TG) content in  
596 explanted liver samples at endpoint. (C, I) Serum ALT. (D, J) Serum AST. (E, K) NAFLD  
597 activity score, (F, L) Hepatic beta-hydroxybutyrate (BHOB). \*P < 0.05, \*\*P < 0.01, \*\*\*P <  
598 0.001, *Slc39a5*<sup>-/-</sup>;*Lepr*<sup>-/-</sup> and corresponding control mice: one-way ANOVA with post hoc  
599 Tukey's test, HFFD or NC: two-way ANOVA with post hoc Tukey's test. Numeric data is  
600 summarized in Suppl. Table 4 and 5.

601  
602 **Fig. 5. Loss of *Slc39a5* results in elevated hepatic zinc and activation of hepatic**  
603 **AMPK signaling in leptin-receptor deficient female mice and female mice**  
604 **challenged with high fat high fructose diet (HFFD).** Analyses were done on explanted  
605 liver samples collected after 16 hours fasting at endpoint in *Lepr*<sup>-/-</sup> (A-C) and HFFD mice  
606 (D-F). (A, D) Immunoblot analysis of hepatic AMPK and AKT activation. AMPK and AKT  
607 signaling is activated in *Lepr*<sup>-/-</sup>;*Slc39a5*<sup>-/-</sup> mice and HFFD *Slc39a5*<sup>-/-</sup> mice (compared to  
608 their *Slc39a5*<sup>+/+</sup> counterparts). (B, E) Hepatic zinc is elevated in *Lepr*<sup>-/-</sup>;*Slc39a5*<sup>-/-</sup> mice  
609 and HFFD *Slc39a5*<sup>-/-</sup> mice (n=10-21). (C, F) Elevated hepatic zinc results in increased  
610 *Mt1* (zinc responsive gene) expression in both models. (G) Immunoblot analysis of  
611 primary human hepatocytes treated with zinc chloride (ZnCl<sub>2</sub>), magnesium chloride  
612 (MgCl<sub>2</sub>), okadaic acid (OA), metformin (Met) for 4 hours. Zinc activated AMPK and AKT  
613 signaling in primary human hepatocytes. (H) Densitometric analysis of immunoblots  
614 (compared to control). \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, ANOVA with post hoc Tukey's  
615 test.

616  
617 **Fig. 6. Loss of *Slc39a5* improves hepatic inflammation and fibrosis in female mice**  
618 **challenged with diet-induced NASH.** *Slc39a5*<sup>-/-</sup> and *Slc39a5*<sup>+/+</sup> mice were placed on a  
619 NASH inducing diet or NC for 40 weeks and sacrificed after 16 hours of fasting. (A, B)  
620 NASH *Slc39a5*<sup>-/-</sup> mice display reduced serum ALT and AST levels. (C-E) Histology scores  
621 for steatosis, hepatocyte hypertrophy, inflammation. (F) NAFLD activity score was

622 reduced in NASH *Slc39a5*<sup>-/-</sup> mice. (G-I) NASH *Slc39a5*<sup>-/-</sup> mice display reduced fibrosis.  
623 (G) Representative images of explanted livers sample stained with picrosirius red  
624 indicative of collagen deposition. Scale bar, 300µm. (H, I) Fibrosis and steatosis-activity-  
625 fibrosis scores. n=6-7 (NC) and 8-11 (NASH), \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, two-  
626 way ANOVA with post hoc Tukey's test. Numeric data is summarized in Suppl. Table 6.




Fig. 1




Fig. 2




Fig. 3






Fig. 4




Fig. 5







Fig.6




**Suppl. Fig. 1. SLC39A5 pLOF variants p.Y47\*(c.141C>G), p.R311\*(c.931C>T), and p.R322\*(c.964C>T) encode for non-functional proteins.** HEK293 cell transfected with expression constructs encoding SLC39A5 wild-type (WT), Y47\*, R311\* and R322\* variants. (A, B) Immunostaining and FACS analysis demonstrating WT SLC39A5 localization to the cell surface. (C) Overexpression of WT SLC39A5 results in Zn<sup>2+</sup> mediated MRE activation in a dose dependent manner, n=4. (D) FACS analyses demonstrating that cell surface expression of SLC39A5 Y47\*, R311\* and R322\* mutants is markedly reduced. (E) Variants Y47\*, R311\* and R322\* did not mediate Zn<sup>2+</sup> induction of MRE, n=8, Statistical comparison to Mock and WT, respectively: \*\*\*P < 0.001, ###P < 0.001, two-way ANOVA with post hoc Tukey's test. Metal regulatory element (MRE), firefly luciferase (Fluc), renilla luciferase (Rluc), cytomegalovirus (CMV), gene of interest (GOI), internal ribosome entry site (IRES).




**Suppl. Fig. 2. Generation and characterization of the *Slc39a5*<sup>-/-</sup> mice.** (A) Schematic representation of the *Slc39a5* null allele. (B) *Slc39a5* gene expression in liver and duodenum of *Slc39a5*<sup>-/-</sup> mice at 20 weeks of age, n=3-6. (C) Immunoblotting analyses demonstrating absence of SLC39A5 protein in liver of *Slc39a5*<sup>-/-</sup> mice at 34 weeks of age. (D-E) Heterozygous loss of *Slc39a5* does not reduce fasting blood glucose in (D) *Lepr*<sup>-/-</sup> mice (at 20 weeks of age) and in (E) mice challenged with high fat high fructose diet (HFFD) for 18 weeks. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, two-way ANOVA with post hoc Tukey's test.



**Suppl. Fig. 3. Loss of *Slc39a5* improves glycemic traits in *Lepr*<sup>-/-</sup> mice and in mice challenged with high fat high fructose diet (HFFD).** Female (A-D, I-L; ♀) and Male (E-H, M-P; ♂) mice. (A-H) *Slc39a5*<sup>-/-</sup>; *Lepr*<sup>-/-</sup> and corresponding control mice. (A-B, E-F) Oral glucose tolerance test (GTT) after 16 hour fasting, at 20 weeks. (C-D, G-H) Intraperitoneal insulin tolerance test (ITT), at 33 weeks. n=5-8. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, one-way ANOVA with post hoc Tukey's test. (I-P) HFFD mice. (I-J, M-N) GTT after 16 hours fasting, at 18 weeks. (K-L, O-P) ITT after 4 hour fasting, at 27 weeks. n=11-12. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, two-way ANOVA with post hoc Tukey's test. Area under curve (AUC). Numeric data is summarized in Suppl. Table 4 and 5.




**Suppl. Fig. 4. Metabolic profiling of female  $Slc39a5^{-/-}; Lepr^{-/-}$  mice.** (A) Longitudinal body weight. (B-D) Analyses were done on explanted liver samples collected after 16 hour fasting at 34 weeks of age. (B) Hepatic expression of fatty acid synthase (*Fasn*) and glucose-6-phosphatase (*G6pc*). (C) Hepatic FASN and G6PC protein levels. (D) Densitometric analysis of hepatic FASN and G6PC. (E) Serum insulin profile upon fasting at 34 weeks of age. (F) Serum insulin profile in fed state at 32 weeks of age. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , ANOVA with post hoc Tukey's test.




**Suppl. Fig. 5. Loss of *Slc39a5* reduces hepatic fatty acid synthase expression but does not change insulin profile of male *Lepr*<sup>-/-</sup> mice.** (A) Longitudinal body weight. (B-D) Analyses were done on explanted liver samples collected after 16 hour fasting at 34 weeks of age. (B) Hepatic expression of *Fasn* and *G6pc*. (C) Hepatic FASN and G6PC protein levels. (D) Densitometric analysis of hepatic FASN and G6PC. (E) Serum insulin profile upon fasting at 34 weeks of age. (F) Serum insulin profile in fed state at 32 weeks of age. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, ANOVA with post hoc Tukey's test.







**Suppl. Fig. 6. Loss of *Slc39a5* reduces hepatic fatty acid synthase expression but does not change insulin profile in female mice challenged with high fat high fructose diet (HFFD).** (A) Longitudinal body weight during dietary intervention. (B-D) Analyses were done on explanted liver samples collected after 16 hour fasting in mice fed HFFD or NC for 30 weeks. (B) Hepatic expression of *Fasn* and *G6pc*. (C) Hepatic FASN and G6PC protein levels. (D) Densitometric analysis of hepatic FASN and G6PC. (E) Fasting serum insulin profile. (F) Fed serum insulin profile. (G) Representative images of *Slc39a5*<sup>-/-</sup> livers stained with H&E. Scale bar, 100um. (H) NAFLD activity score. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, two-way ANOVA with post hoc Tukey's test.




**Suppl. Fig. 7. Loss of *Slc39a5* reduces hepatic fatty acid synthase expression but does not change insulin profile in male mice challenged with high fat high fructose diet (HFFD).** (A) Longitudinal body weight during dietary intervention. (B-D) Analyses were done on explanted liver samples collected after 16 hour fasting in mice fed HFFD or NC for 30 weeks. (B) Hepatic expression of *Fasn* and *G6pc*. (C) Hepatic FASN and G6PC protein levels. (D) Densitometric analysis of hepatic FASN and G6PC. (E) Fasting serum insulin profile. (F) Fed serum insulin profile. (G) Representative images of *Slc39a5*<sup>+/+</sup> livers stained with H&E. Scale bar, 100um. (H) NAFLD activity score. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, two-way ANOVA with post hoc Tukey's test.




**Suppl. Fig. 8. Additional data of glucose stimulated insulin secretion, serum BHOB and pancreas histology in mouse models.** (A-H) Oral glucose tolerance test (GTT) was performed in *Slc39a5<sup>-/-</sup>* female (A-D) and male (E-H) mice after 16 hour fasting, at 15 weeks. Glucose (A-B, E-F) and insulin (C-D, G-H) levels were measured at 0, 15 and 60 mins.  $n=6-8$ . (I-J) Serum BHOB levels in female (I) and male (J) mice challenged with high fat high fructose diet (HFFD). \* $P < 0.05$ , \*\*\* $P < 0.001$ , two-way ANOVA with post hoc Tukey's test. (K-L) Serum BHOB levels in *Slc39a5<sup>-/-</sup>; Lepr<sup>-/-</sup>* female (K) and male (L) mice. \* $P < 0.05$ , \*\*\* $P < 0.001$ , one-way ANOVA with post hoc Tukey's test. (M-N) No overt morphological deficits in pancreas resulting from *Slc39a5* deficiency. Scale bar, 300 $\mu$ m




**Suppl. Fig. 9. Loss of *Slc39a5* improves liver function and steatosis in *Lepr*<sup>-/-</sup> male mice and reduces hepatic triglyceride in male mice challenged with high fat high fructose diet (HFFD).** *Slc39a5*<sup>-/-</sup>; *Lepr*<sup>-/-</sup> and corresponding control mice (A-F) were sacrificed after 16 hours fasting at 34 weeks of age. (G-L) *Slc39a5*<sup>-/-</sup> and corresponding control mice were fed HFFD or NC for 30 weeks and sacrificed after 16 hours fasting. (A, G) Representative images of livers stained with H&E. Scale bar, 200µm. (B, H) Hepatic triglyceride (TG) content in explanted liver samples at endpoint. (C, I) Serum ALT. (D, J) Serum AST. (E, K) NAFLD activity score, (F, L) Hepatic beta-hydroxybutyrate (BHOB). \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, *Slc39a5*<sup>-/-</sup>; *Lepr*<sup>-/-</sup> mice: one-way ANOVA with post hoc Tukey's test, HFFD: two-way ANOVA with post hoc Tukey's test. Numeric data is summarized in Suppl. Table 4 and 5.




**Suppl. Fig. 10. Loss of *Slc39a5* results in elevated hepatic zinc and activation of hepatic AMPK signaling in congenital and diet-induced obesity models.** Analyses were done on explanted liver samples collected from male mice after 16 hour fasting at endpoint of congenital (A-C) and diet-induced obesity (D-F). (A, D) Immunoblot analysis of hepatic AMPK and AKT activation. (B, E) Hepatic zinc measurements (n=10-21). (C, F) Hepatic *Mt1* gene expression. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, ANOVA with post hoc Tukey's test.






**Suppl. Fig. 12. Loss of *Slc39a5* does not alter hepatic magnesium, iron, copper, calcium and cobalt levels in mice challenged with high fat high fructose diet (HFFD).** Female (A-C) and male (D-F) mice were fed HFFD or NC for 30 weeks. (A, D) Densitometric analysis of hepatic AMPK and AKT. (B, E) Hepatic gene expression of *Slc39a5* and *Mt2*. (C, F) Hepatic ion quantification by flame atomic absorption spectrometry. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, two-way ANOVA with post hoc Tukey's test.




**Suppl. Fig. 13. Zinc activates AMPK and AKT signaling in time-dependent and dose-dependent manner.** (A) No differences in cell viability observed in human primary hepatocytes (after 4hr treatment) across different experimental groups. (B) Time-resolved (0-4hr) immunoblotting analyses of primary human hepatocytes treated with zinc chloride. (C) Immunoblots of HepG2 treated with zinc chloride (ZnCl<sub>2</sub>) and magnesium chloride (MgCl<sub>2</sub>). (D) Time-resolved (0-4hr) immunoblotting analyses of HepG2 treated with zinc chloride. Okadaic acid (OA), metformin (Met), N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine (TPEN).






**Suppl. Fig. 14. Elevated hepatic zinc results in reduced protein phosphatase activity.** Analyses were done on explanted liver samples collected after 16 hour fast at endpoint of congenital obesity (A-B) and diet-induced obesity (C-D) challenges. Female (A, C) and Male (B, D) mice. (A-D) Ser/Thr and Tyr protein phosphatase activity. (E) Ser/Thr and Tyr protein phosphatase activity in primary human hepatocytes treated with zinc chloride (ZnCl<sub>2</sub>), magnesium chloride (MgCl<sub>2</sub>) and N,N,N',N'-Tetrakis(2-pyridylmethyl)ethylenediamine (TPEN) for 4 hours. \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, ANOVA with post hoc Tukey's test.



**Suppl. Fig. 15. Loss of *Slc39a5* reduces hepatic inflammation and fibrosis in male mice challenged with diet-induced NASH.** Mice were fed NASH diet or NC for 40 weeks and sacrificed after 16 hour fasting. (A-B) Loss of *Slc39a5* reduces serum ALT and AST levels (biomarkers of liver damage). (C-E) Histology scores for steatosis, hepatocyte hypertrophy, inflammation. (F) NAFLD activity score. (G-I) Loss of *Slc39a5* improves fibrosis in mice upon NASH dietary challenge. (G) Representative images of explanted livers sample stained with picosirius red indicative of collagen deposition. Scale bar, 300μm. (H-I) Histology score for fibrosis and steatosis-activity-fibrosis score. n=7-10 (NC) and 15-17 (NASH), \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, two-way ANOVA with post hoc Tukey's test. Numeric data is summarized in suppl. Table 6.



**Suppl. Fig. 16. Loss of *Slc39a5* improves liver function in mice challenged with diet-induced NASH.** Female (A-E) and Male (F-J) mice. (A, F) Body weight. (B, G) Fasting blood glucose. (C, H) Serum zinc. (D, I) Hepatic zinc. (E, J) Total hepatic SOD activity. n=6-10 (NC) and 8-17 (NASH), \*P < 0.05, \*\*P < 0.01, \*\*\*P < 0.001, two-way ANOVA with post hoc Tukey's test.

Measure	Zinc		Insulin, pM		Proinsulin, pM		C-Peptide, pM		Proinsulin/Insulin		Insulin/C-Peptide		Glucose	
	Ref	Het	Ref	Het	Ref	Het	Ref	Het	Ref	Het	Ref	Het	Ref	Het
<b>SLC39A5</b>														
<b>Mean</b>	1.576	1.766	112.6	118.7	30.95	28.65	661.8	629.6	0.3222	0.2895	0.2331	0.2336	106.6	106.6
<b>Median</b>	1.513	1.744	70.5	82.05	18	16.7	475.1	480.6	0.258	0.239	0.145	0.154	103	106
<b>N</b>	248	90	246	86	253	91	253	91	246	86	247	86	247	87
<b>P values</b>	0.0024		0.682		0.5994		0.6449		0.2249		0.9924		0.9912	

**Suppl. Table 1. Serum zinc and insulin profile assessment in the serum call back study.** Serum zinc levels in SLC39A5 heterozygous loss of function carriers are elevated by 12% as compared to age, sex, BMI-matched reference controls. Analyses of insulin production (insulin/c-peptide ratio), insulin clearance (proinsulin/insulin) and blood glucose in these samples demonstrated no differences based on genotype. Data represented in a graphical format in Fig. 1.

Tissues	Human		Mouse															
	Normal Adult		Adult Female						Adult Male									
	ug/g	uM	Sic39a5 <sup>+/+</sup>		Sic39a5 <sup>-/-</sup>		P values (Sic39a5 <sup>+/+</sup> vs Sic39a5 <sup>-/-</sup> )		Sic39a5 <sup>+/+</sup>		Sic39a5 <sup>-/-</sup>		P value summary		Sic39a5 <sup>-/-</sup>		P values (Sic39a5 <sup>+/+</sup> vs Sic39a5 <sup>-/-</sup> )	
			ug/g	uM	ug/g	uM	ug/g	uM	ug/g	uM	ug/g	uM	ug/g	uM	ug/g	uM		
Plasma/serum	1	15	1.0 ± 0.1	15 ± 1.5	3.7 ± 0.4	57.0 ± 6.1	***	1.2 ± 0.2	18.9 ± 2.3	***	1.1 ± 0.1	16.5 ± 1.5	3.5 ± 0.2	54 ± 3.1	***	1.3 ± 0.1	20.2 ± 1.3	**
Liver	58	887	26.7 ± 4.4	408 ± 67.3	45.5 ± 2.2	696 ± 33.6	***	29.4 ± 4.5	449 ± 68.3	n.s.	28.2 ± 2.4	431 ± 36.7	36.9 ± 2.4	564 ± 36.7	**	29.2 ± 1.9	446 ± 29.6	n.s.
Skeletal muscle	51	780	10.0 ± 1.2	153 ± 1.2	11.2 ± 1.2	171 ± 18.4	n.s.	10.8 ± 0.7	164 ± 10.6	n.s.	8.4 ± 0.7	128 ± 10.7	8.6 ± 1.6	132 ± 24.5	n.s.	7.8 ± 1.2	118 ± 17.7	n.s.
Bone	100	1530	113 ± 12.5	1728 ± 191	429 ± 58.4	6562 ± 893	***	145 ± 12.9	2217 ± 197	**	98.5 ± 8.6	1506 ± 131	378 ± 55.3	5777 ± 646	***	114 ± 8.8	1743 ± 134	*
Brain	11	168	16.5 ± 0.7	252 ± 11.2	18.1 ± 1.7	277 ± 25.7	**	N/A	N/A	N/A	16.9 ± 0.7	259 ± 10.2	18.0 ± 1.5	275 ± 22.9	*	N/A	N/A	N/A
Kidney	55	841	15.2 ± 0.4	232 ± 6.1	17.3 ± 0.3	265 ± 4.6	***	15.4 ± 0.3	235 ± 5.1	n.s.	16.2 ± 0.2	248 ± 3.1	17.8 ± 0.5	272 ± 7.6	***	16.4 ± 0.4	251 ± 6.6	n.s.
Pancreas	N/A	N/A	45.6 ± 7.2	697 ± 110	29.7 ± 1.3	454 ± 19.9	**	48.4 ± 9.2	739 ± 140	n.s.	40.4 ± 3.0	618 ± 45.9	26.9 ± 2.6	411 ± 39.8	***	38.9 ± 2.1	595 ± 31.9	n.s.
Fat	N/A	N/A	<0.3	N/A	<0.3	N/A	N/A	<1.0	N/A	N/A	<0.3	N/A	<0.3	N/A	N/A	<1.0	N/A	N/A

**Suppl. Table 2: Tissue zinc content in human and mouse.** Human data adapted from Jackson et al.<sup>4</sup>. \*p<0.05; \*\*p<0.01, \*\*\*p<0.001, not significant (n.s.), unpaired t-test. Values represent mean ± SD.

Serum Chemistry (40 weeks of age)	Female						Male						
	Slc39a5 <sup>+/+</sup> (n=6)			Slc39a5 <sup>-/-</sup> (n=6)			Slc39a5 <sup>+/+</sup> (n=6)			Slc39a5 <sup>-/-</sup> (n=6)			
	Mean	SEM	P values	Mean	SEM	Fold Change (KOWT)	Mean	SEM	P values	Mean	SEM	Fold Change (KOWT)	P values
ALT (U/l)	43.00	5.99	n.s.	35.90	7.17	0.83	79.20	12.08	n.s.	67.00	13.01	0.85	n.s.
AST (U/l)	147.00	21.49	n.s.	180.60	53.50	1.23	133.73	14.10	n.s.	130.29	16.20	0.97	n.s.
Albumin (g/dl)	3.48	0.12	n.s.	3.68	0.11	1.06	4.13	0.09	n.s.	3.98	0.17	0.96	n.s.
Alkaline Phosphatase (U/l)	113.50	10.09	n.s.	132.17	9.12	1.16	95.00	6.56	n.s.	95.67	10.31	1.01	n.s.
Alanine Transaminase (U/l)	46.17	13.62	n.s.	61.50	16.07	1.33	129.00	16.43	n.s.	53.83	17.84	0.42	*
Aspartate Transaminase (U/l)	169.50	24.64	n.s.	192.17	37.17	1.13	263.33	29.68	n.s.	185.17	44.63	0.70	n.s.
Amylase (U/l)	3960.67	871.83	n.s.	2864.20	368.35	0.72	3317.40	272.77	n.s.	2843.00	94.59	0.86	n.s.
Blood Urea Nitrogen (mg/dl)	20.50	0.89	n.s.	21.83	0.65	1.07	23.00	0.52	n.s.	25.33	0.33	1.10	*
Creatinine (mg/dl)	0.13	0.02	n.s.	0.16	0.02	1.22	0.18	0.02	n.s.	0.18	0.01	1.03	n.s.
Total Protein (g/dl)	5.23	0.20	*	5.77	0.10	1.10	6.23	0.12	*	5.83	0.22	0.94	n.s.
Uric Acid (mg/dl)	1.28	0.20	n.s.	1.62	0.09	1.26	2.75	0.30	n.s.	2.25	0.27	0.82	n.s.
Chloride (mmol/l)	103.67	1.58	n.s.	104.67	1.33	1.01	106.50	0.67	n.s.	106.50	2.05	1.00	n.s.
Potassium (mmol/l)	8.68	0.29	n.s.	9.38	0.57	1.08	10.00	0.46	n.s.	11.35	0.43	1.14	n.s.
Sodium (mmol/l)	145.00	2.45	n.s.	147.17	2.29	1.01	149.67	1.33	n.s.	147.00	2.49	0.98	n.s.
Calcium (mg/dl)	9.27	0.25	n.s.	9.73	0.22	1.05	10.07	0.16	n.s.	9.93	0.22	0.99	n.s.
Magnesium (mg/dl)	2.57	0.13	n.s.	2.93	0.11	1.14	3.00	0.18	n.s.	3.20	0.12	1.07	n.s.
Iron (ug/dl)	90.67	8.40	n.s.	94.00	7.41	1.04	114.00	6.88	n.s.	99.33	4.74	0.87	n.s.

**Suppl. Table 3: No differences in serum chemistry profile of Slc39a5<sup>+/+</sup> and Slc39a5<sup>-/-</sup> mice.** Serum chemistry analysis in adult mice (40 weeks of age, both sexes) demonstrated no differences in pancreatic amylase, renal function parameters (blood urea nitrogen, creatinine, total protein and uric acid) and electrolytes (chloride, potassium and sodium) or liver enzymes (alanine aminotransferase; ALT and aspartate aminotransferase; AST).

	Sex	<i>Slc39a5</i> <sup>+/+</sup>	<i>Slc39a5</i> <sup>-/-</sup>	% change in <i>Slc39a5</i> <sup>-/-</sup> to <i>Slc39a5</i> <sup>+/+</sup>	P value	<i>Lepr</i> <sup>-/-</sup>	% change in <i>Lepr</i> <sup>-/-</sup> to <i>Slc39a5</i> <sup>+/+</sup>	P value	<i>Slc39a5</i> <sup>-/-</sup> ; <i>Lepr</i> <sup>-/-</sup>	% change in <i>Slc39a5</i> <sup>-/-</sup> ; <i>Lepr</i> <sup>-/-</sup> to <i>Lepr</i> <sup>-/-</sup>	P value
BW (g) at 34 weeks	F	26.65 ± 0.92	27.30 ± 0.78	2%	n.s.	69.32 ± 2.24	160%	***	65.36 ± 1.92	-6%	n.s.
	M	36.03 ± 1.41	33.82 ± 1.24	-6%	n.s.	65.48 ± 1.49	82%	***	59.38 ± 2.48	-9%	n.s.
Hepatic Zinc (ug/g)	F	37.93 ± 1.17	55.56 ± 2.34	46%	***	25.53 ± 0.69	-33%	***	32.04 ± 1.35	26%	**
	M	37.79 ± 1.14	45.89 ± 1.22	21%	**	23.91 ± 1.19	-37%	***	34.96 ± 1.98	46%	***
Fasting Blood Glucose (mg/dL)	F	142.88 ± 5.46	114.20 ± 8.19	-20%	n.s.	237.63 ± 13.54	66%	***	173.00 ± 11.65	-27%	**
	M	167.75 ± 10.00	162.50 ± 7.89	-3%	n.s.	245.78 ± 8.60	47%	***	207.75 ± 8.08	-15%	*
GTT AUC (x10 <sup>3</sup> )	F	28.63 ± 0.86	26.70 ± 1.22	-7%	n.s.	67.74 ± 2.86	137%	***	50.55 ± 2.34	-25%	***
	M	35.75 ± 1.84	35.36 ± 1.34	-1%	n.s.	69.38 ± 2.54	94%	***	59.48 ± 3.27	-14%	*
ITT AUC (x10 <sup>3</sup> )	F	18.38 ± 0.71	17.25 ± 0.37	-6%	n.s.	60.83 ± 7.71	231%	***	40.66 ± 5.27	-33%	*
	M	25.79 ± 1.17	25.30 ± 1.04	-2%	n.s.	58.55 ± 3.74	127%	***	61.60 ± 1.66	5%	n.s.
HOMA-IR	F	7.06 ± 1.94	2.16 ± 0.67	-69%	n.s.	229.79 ± 29.97	3153%	***	60.32 ± 16.58	-74%	***
	M	13.44 ± 3.10	15.26 ± 3.54	14%	n.s.	228.10 ± 26.37	1597%	***	138.12 ± 14.78	-39%	**
Ratio (proinsulin/insulin)	F	0.19 ± 0.03	0.18 ± 0.03	-4%	n.s.	0.55 ± 0.23	196%	n.s.	0.27 ± 0.11	-51%	n.s.
	M	0.16 ± 0.05	0.13 ± 0.03	-20%	n.s.	0.48 ± 0.18	190%	n.s.	0.29 ± 0.13	-40%	n.s.
Ratio (insulin/c-peptide)	F	0.53 ± 0.12	0.55 ± 0.05	2%	n.s.	1.06 ± 0.13	99%	n.s.	1.27 ± 0.50	19%	n.s.
	M	2.08 ± 1.45	1.15 ± 0.33	-45%	n.s.	2.20 ± 0.48	6%	n.s.	1.17 ± 0.35	-47%	n.s.
ALT (U/L)	F	31.64 ± 3.43	51.90 ± 11.25	64%	n.s.	393.53 ± 31.59	1144%	***	200.94 ± 22.66	-49%	***
	M	34.46 ± 2.84	46.08 ± 13.00	34%	n.s.	365.11 ± 29.73	959%	***	223.27 ± 22.89	-39%	***
AST (U/L)	F	136.91 ± 19.22	150.00 ± 14.57	10%	n.s.	514.47 ± 74.33	276%	***	264.06 ± 22.23	-49%	***
	M	104.92 ± 7.13	93.83 ± 16.83	-11%	n.s.	400.72 ± 35.12	282%	***	251.07 ± 23.50	-37%	***
NAFLD activity score	F	1.20 ± 0.36	1.50 ± 0.22	25%	n.s.	9.25 ± 0.18	671%	***	7.25 ± 0.58	-22%	**
	M	1.25 ± 0.25	1.25 ± 0.25	0%	n.s.	9.36 ± 0.13	649%	***	7.15 ± 0.83	-24%	*
Hepatic TG (mg/g)	F	14.73 ± 1.53	15.82 ± 3.28	7%	n.s.	67.11 ± 3.01	356%	***	29.24 ± 3.29	-56%	***
	M	23.64 ± 2.61	25.37 ± 2.63	7%	n.s.	81.12 ± 5.56	243%	***	55.98 ± 3.65	-31%	***

**Suppl. Table 4 Summary statistics for the congenital obesity model.** Loss of *Slc39a5* improves glycemic traits and liver function in leptin-receptor (*Lepr*) deficient mice. Loss of *Slc39a5* does not change insulin production (proinsulin/insulin), insulin clearance (insulin/c-peptide ratio). Data represented in a graphical format in Fig. 3, 4 and Suppl. Fig 5, 6.

	Sex	<i>Slc39a5</i> <sup>+/+</sup> (NC)	<i>Slc39a5</i> <sup>-/-</sup> (NC)	% change in <i>Slc39a5</i> <sup>-/-</sup> (NC) to <i>Slc39a5</i> <sup>+/+</sup> (NC)	P value	<i>Slc39a5</i> <sup>+/+</sup> (HFFD)	% change in <i>Slc39a5</i> <sup>+/+</sup> (HFFD) to <i>Slc39a5</i> <sup>+/+</sup> (NC)	P value	<i>Slc39a5</i> <sup>-/-</sup> (HFFD)	% change in <i>Slc39a5</i> <sup>-/-</sup> (HFFD) to <i>Slc39a5</i> <sup>-/-</sup> (NC)	P value
BW (g), diet for 30 weeks	F	27.32 ± 0.61	26.53 ± 0.87	-3%	n.s.	47.51 ± 1.10	74%	***	46.65 ± 1.66	-2%	n.s.
	M	40.03 ± 0.42	35.70 ± 1.48	-11%	**	49.95 ± 0.91	25%	***	49.74 ± 0.79	0%	n.s.
Hepatic Zinc (ug/g)	F	30.39 ± 1.38	43.82 ± 1.92	44%	**	32.73 ± 1.22	8%	n.s.	47.08 ± 3.44	44%	***
	M	27.91 ± 0.76	38.60 ± 1.49	38%	***	27.07 ± 1.20	-3%	n.s.	31.59 ± 1.19	17%	n.s.
Fasting Blood Glucose (mg/dL)	F	122.82 ± 6.73	119.50 ± 8.04	-3%	n.s.	188.36 ± 8.24	53%	***	154.67 ± 7.28	-18%	*
	M	151.50 ± 6.85	143.91 ± 6.35	-5%	n.s.	201.08 ± 5.59	33%	***	175.83 ± 3.52	-13%	*
GTT AUC (x10 <sup>3</sup> )	F	30.33 ± 1.16	27.14 ± 1.26	-11%	n.s.	39.20 ± 1.74	29%	***	32.26 ± 0.76	-18%	**
	M	37.44 ± 0.88	36.59 ± 1.28	-2%	n.s.	44.70 ± 2.85	19%	*	37.33 ± 1.48	-16%	*
ITT AUC (x10 <sup>3</sup> )	F	16.56 ± 0.81	15.80 ± 1.03	-5%	n.s.	21.32 ± 0.72	29%	***	17.43 ± 0.45	-18%	**
	M	23.18 ± 1.10	20.87 ± 0.73	-10%	n.s.	29.05 ± 1.14	25%	***	25.22 ± 0.87	-13%	*
HOMA-IR	F	2.42 ± 0.38	1.88 ± 0.36	-22%	n.s.	16.20 ± 2.61	569%	***	10.27 ± 1.24	-37%	*
	M	12.14 ± 2.64	7.65 ± 1.59	-37%	n.s.	31.69 ± 3.93	161%	***	17.97 ± 2.07	-43%	**
Ratio (proinsulin/insulin)	F	0.20 ± 0.03	0.23 ± 0.03	17%	n.s.	0.20 ± 0.03	-1%	n.s.	0.31 ± 0.05	57%	n.s.
	M	0.16 ± 0.04	0.14 ± 0.02	-10%	n.s.	0.18 ± 0.04	13%	n.s.	0.16 ± 0.03	-13%	n.s.
Ratio (insulin/c-peptide)	F	0.70 ± 0.09	0.54 ± 0.11	-22%	n.s.	1.04 ± 0.10	50%	*	0.70 ± 0.05	-32%	*
	M	1.52 ± 0.26	1.82 ± 0.50	20%	n.s.	2.89 ± 0.82	90%	n.s.	2.06 ± 0.45	-29%	n.s.
ALT (U/L)	F	49.46 ± 7.98	60.83 ± 10.80	23%	n.s.	241.94 ± 13.84	389%	***	148.71 ± 13.89	-39%	***
	M	126.71 ± 10.10	84.00 ± 16.84	-34%	n.s.	388.14 ± 30.94	206%	***	353.64 ± 41.42	-9%	n.s.
AST (U/L)	F	173.50 ± 15.07	216.83 ± 33.49	25%	n.s.	449.71 ± 30.60	159%	***	370.79 ± 34.35	-18%	n.s.
	M	276.40 ± 29.93	228.47 ± 25.98	-17%	n.s.	489.79 ± 37.65	77%	***	458.36 ± 44.22	-6%	n.s.
NAFLD activity score	F	4.50 ± 0.72	2.50 ± 0.72	-44%	n.s.	8.33 ± 0.33	85%	**	3.33 ± 0.71	-60%	***
	M	5.50 ± 0.43	1.83 ± 0.75	-67%	**	7.83 ± 0.70	42%	n.s.	8.67 ± 0.80	11%	n.s.
Hepatic TG (mg/g)	F	23.42 ± 2.64	22.36 ± 1.80	-5%	n.s.	43.53 ± 1.09	86%	***	28.42 ± 1.74	-35%	***
	M	41.52 ± 2.11	36.29 ± 2.76	-13%	n.s.	83.01 ± 2.59	100%	***	60.41 ± 2.60	-27%	***

**Suppl. Table 5 Summary statistics for the diet-induced obesity model.** Loss of *Slc39a5* improves glycemic traits and liver function in mice upon a high fat high fructose diet (HFFD) dietary challenge. Moreover, loss of *Slc39a5* does not change insulin production (proinsulin/insulin), insulin clearance (insulin/c-peptide ratio). Data represented in a graphical format in Fig. 3, 4 and Suppl. Fig 7, 8.



	Sex	<i>Slc39a5</i> <sup>+/+</sup> (NC)	<i>Slc39a5</i> <sup>-/-</sup> (NC)	% change in <i>Slc39a5</i> <sup>-/-</sup> (NC) to <i>Slc39a5</i> <sup>+/+</sup> (NC)	P value	<i>Slc39a5</i> <sup>+/+</sup> (NASH)	% change in <i>Slc39a5</i> <sup>+/+</sup> (NASH) to <i>Slc39a5</i> <sup>+/+</sup> (NC)	P value	<i>Slc39a5</i> <sup>-/-</sup> (NASH)	% change in <i>Slc39a5</i> <sup>-/-</sup> (NASH) to <i>Slc39a5</i> <sup>+/+</sup> (NASH)	P value
BW (g), 40 weeks on diets	F	31.30 ± 0.81	29.07 ± 2.72	-7%	n.s.	43.41 ± 2.45	39%	**	43.97 ± 1.97	1%	n.s.
	M	41.35 ± 3.02	34.95 ± 4.13	-15%	**	51.59 ± 3.61	25%	***	51.05 ± 4.14	-1%	n.s.
Hepatic Zinc (ug/g)	F	25.97 ± 2.02	38.16 ± 3.28	47%	***	22.44 ± 2.17	-14%	n.s.	31.80 ± 6.49	42%	***
	M	24.89 ± 1.88	35.20 ± 3.33	41%	***	21.19 ± 1.69	-15%	***	25.81 ± 2.02	22%	***
ALT (U/L)	F	127.43 ± 91.14	98.83 ± 62.83	-22%	n.s.	577.63 ± 133.13	353%	***	322.27 ± 153.68	-44%	***
	M	155.90 ± 59.44	101.29 ± 65.38	-35%	n.s.	653.59 ± 117.96	319%	***	511.40 ± 85.79	-22%	***
AST (U/L)	F	317.86 ± 175.02	314.67 ± 186.03	-1%	n.s.	890.88 ± 230.64	180%	***	574.00 ± 218.13	-36%	*
	M	257.90 ± 62.48	191.86 ± 61.30	-26%	n.s.	724.35 ± 123.06	181%	***	564.47 ± 137.77	-22%	**
FBG	F	129.00 ± 22.66	113.17 ± 29.82	-12%	n.s.	175.38 ± 20.64	36%	**	129.27 ± 19.53	-26%	***
	M	140.30 ± 11.49	127.13 ± 12.49	-9%	n.s.	186.00 ± 23.65	33%	***	149.13 ± 14.33	-20%	***
Macrovesicular steatosis score	F	2.43 ± 0.19	0.83 ± 0.75	-66%	***	2.50 ± 0.27	3%	n.s.	2.40 ± 0.46	-4%	n.s.
	M	1.90 ± 0.84	1.36 ± 0.94	-29%	n.s.	2.71 ± 0.25	42%	**	2.73 ± 0.26	1%	n.s.
Hepatocyte hypertrophy score	F	1.71 ± 0.49	0.50 ± 0.45	-71%	***	3.00 ± 0.00	75%	***	2.50 ± 0.63	-17%	n.s.
	M	1.50 ± 0.85	1.07 ± 1.10	-29%	n.s.	3.00 ± 0.00	100%	***	3.00 ± 0.00	0%	n.s.
Inflammation score	F	0.86 ± 0.24	0.25 ± 0.27	-71%	n.s.	2.19 ± 0.53	155%	***	1.36 ± 0.64	-38%	**
	M	0.70 ± 0.54	0.43 ± 0.61	-39%	n.s.	2.56 ± 0.30	266%	***	1.80 ± 0.32	-30%	***
NAFLD activity score	F	5.00 ± 0.58	1.58 ± 1.28	-68%	***	7.69 ± 0.70	54%	***	6.23 ± 1.49	-19%	**
	M	4.10 ± 2.14	2.86 ± 2.59	-30%	n.s.	8.26 ± 0.31	102%	***	7.67 ± 0.31	-7%	n.s.
Fibrosis score	F	0.29 ± 0.39	0.25 ± 0.42	-13%	n.s.	2.50 ± 0.53	775%	***	1.27 ± 0.52	-49%	***
	M	0.30 ± 0.48	0.14 ± 0.24	-52%	n.s.	2.82 ± 0.35	841%	***	2.20 ± 0.46	-22%	***
Steatosis-activity-fibrosis score	F	5.29 ± 0.81	1.83 ± 1.60	-65%	***	10.25 ± 0.76	94%	***	7.41 ± 1.51	-28%	***
	M	4.40 ± 2.40	3.00 ± 2.81	-32%	n.s.	11.09 ± 0.36	152%	***	9.87 ± 0.58	-11%	n.s.

**Suppl. Table 6 Summary statistics for the diet-induced NASH model.** Loss of *Slc39a5* improves hepatic inflammation and fibrosis in both female and male mice challenged with diet-induced NASH. Data represented in a graphical format in Fig. 6 and Suppl. Fig 14.

## Supplementary Methods

### Human Genetic Studies and Phenotyping

The Geisinger Health System DiscovEHR study is a hospital-based cohort of patients of the GHS, a large healthcare provision network in Central and Eastern Pennsylvania, United States. More than 200,000 health system participants have been enrolled and >145,000 have had exome sequencing performed by Regeneron Genetics Center. Type 2 diabetes (T2D) cases in DiscovEHR were defined as individuals with an ICD9 (code 250) or ICD10 (code E11) code for T2D, and either a median HbA1c value greater than or equal to 6.5%, or with a prescription for any diabetic medication. Individuals were excluded from the case pool if they had both an ICD10 code for type 1 diabetes (T1D; code E10) and if they did not have a prescription for any oral hypoglycemic medication. Controls were defined as individuals with no ICD codes for T1D or T2D, a median HbA1c value of less than 5.7%, and with no record of a prescription for any diabetic medication.

The UK Biobank is a prospective biomedical study of ~500,00 adults from across the UK, including extensive phenotype measures and genomic data. T2D in UK Biobank was defined in line with a previously reported definition in this cohort<sup>1,2</sup>. The UKB self-reported data were used to identify individuals with “probable type 2 diabetes”, “possible type 2 diabetes”, “probable type 1 diabetes” or “possible type 1 diabetes”, using a previously published algorithm<sup>1</sup>. T2D cases were defined as individuals with “probable type 2 diabetes” on self-report, or an ICD10 code E11 for T2D. Individuals were excluded from the analysis if they had “probable type 1 diabetes”, “possible type 1 diabetes”, or ICD10 code E10, for T1D.

The BioMe study (SINAI) is a highly diverse electronic health record (EHR)-linked biobank of over 50,000 participants from the Mount Sinai Health System (MSHS) in New York, NY. T2D cases in BioMe were defined as individuals meeting at least two of the following three criteria: 1) ICD10 code for T2D (code E11 and/or O24.1), 2) a blood value in keeping with diabetes (median HbA1c value greater than or equal to 6.5% and/or median random glucose greater than or equal to 200 mg/dL), and 3) a prescription for any diabetic medication. Individuals were excluded from the case pool if they had an ICD10 code for

T1D (code E10 and/or O24.0) or if they had a record of having received an outpatient prescription for insulin (and no record of other antidiabetic medication). Controls were defined as individuals with no ICD10 codes for any type of diabetes mellitus or a family history of diabetes, median HbA1c value of less than 5.7%, median random glucose of less than 200 mg/dL, no oral glucose tolerance test in pregnancy exceeding a diagnostic threshold for gestational diabetes, and no record of a prescription for any diabetic medication.

The Malmö Diet and Cancer Study (MDCS) is a prospective study of ~53,000 adults living in Malmö, Sweden<sup>3</sup>. T2D cases in MDCS were defined as individuals meeting at least two of the following four criteria: 1) ICD10 code for T2D (code E11 and/or O24.1) or T2D noted in diabetes registries, 2) a blood value in keeping with diabetes (HbA1c value greater than or equal to 6.5% and/or fasting glucose greater than or equal to 126 mg/dL), 3) a prescription for non-insulin diabetic medication, and 4) a record of a non-specific diabetes event (e.g. reported at baseline, or extracted from a registry) with an age at diagnosis, or start of treatment, of greater than or equal to 35 years. Individuals were excluded from the case pool if they had an ICD10 code for T1D (code E10 and/or O24.0), or T1D noted in a diabetes registry, or if they had a record of having received insulin with no record of other antidiabetic medication. Controls were defined as individuals with no ICD10 codes for any type of diabetes mellitus, no family history of diabetes, no other variables indicating a potential diagnosis of diabetes, HbA1c value of less than 5.7%, fasting glucose of less than 100 mg/dL, and no record of a prescription for any diabetic medication.

### **Association analyses**

Rank-based inverse normal transformed (RINT) quantitative measures (including all subjects and sex-stratified models) with non-missing phenotype information were assessed using an additive mixed model implemented in REGENIE v2<sup>4</sup>. Prior to normalization, traits were adjusted for a standard set of covariates including age, age<sup>2</sup>, sex, age×sex, age<sup>2</sup>×sex, 10 common variant genetic principal components and 20 genetic principal components derived from rare variants. Binary outcomes were similarly

adjusted for age, age<sup>2</sup>, sex, age×sex, age<sup>2</sup>×sex, 10 common variant genetic principal components and 20 genetic principal components derived from rare variants and tested for association using a generalized mixed model implemented in REGENIE v2. Following analysis within each cohort, we performed inverse variance-weighted meta-analysis for T2D using METAL.

### **GHS serum Call Back Study**

As an orthogonal biochemical assessment of the EHS reported blood analyte data, a serum callback study was designed to evaluate serum zinc, blood glucose, insulin synthesis (proinsulin/insulin ratio) and clearance (insulin/c-peptide ratio) in heterozygous carriers of SLC39A5 pLOF variants. Carriers of pLOF variants in SLC39A5 among exome-sequenced participants of European ancestry in the Regeneron Genetics Center-Geisinger Health System DiscovEHR study were included. Controls included non-carriers of pLOF variants in SLC39A5 and SLC30A8 or the common T2D risk variant rs13266634 in SLC30A8 and non-carrier first degree relatives of study subjects. Participants with T1D or T2D diagnoses were excluded. Furthermore, two non-carriers were selected for each carrier matching sex, age (+/- 5years) and BMI (+/- 5). A total of 22 SLC39A5 LOF variants in 131 carriers and 262 matched non-carriers were identified, however sample (frozen fasting serum) availability limited analyses to ~250 non-carriers and ~90 carriers as shown in Supplementary Table 1. Serum insulin was measured using Human Insulin ELISA kit (Millipore, EZHI-14BK), proinsulin using Human Total Proinsulin ELISA kit (Millipore, EZHPI-15BK), and c-peptide using Human c-peptide ELISA kit (Abcam, ab178611). Serum zinc was measured using flame atomic absorption spectroscopy as described below. Blood glucose was evaluated using ADVIA Chemistry Glucose Hexokinase\_3 reagents (REF 050011429) on a Siemens ADVIA Chemistry XPT analyzer.

### **Generation of *Slc39a5* loss of function mice**

The genetically engineered *Slc39a5*<sup>-/-</sup> mouse strain was created using Regeneron's VelociGene® technology<sup>5, 6</sup>. Briefly, C57Bl/6NTac embryonic stem cells (ESC) were targeted for ablation of a portion of *Slc39a5*, beginning just after the initiating

ATG and ending 5 base pairs before the 3' end of coding exon 2. This region contains the SLC39A5 signal peptide and much of the N-terminal extracellular domain. A lacZ reporter module was inserted in frame with *Slc39a5*'s initiating Methionine codon, followed by a self-deleting fLoxed neomycin resistance (neo) cassette for selection in mouse C57BL/6NTac embryonic stem cells. The targeted cells were microinjected into 8-cell embryos from Charles River Laboratories Swiss Webster albino mice, yielding F0 VelociMice® that were 100% derived from the targeted cells<sup>5</sup>. These mice were subsequently bred to F1, at which point the self deleting neo cassette was also removed in the male germline. F1 heterozygotes were utilized to generate experimental cohorts, including *Slc39a5*<sup>-/+</sup> heterozygous mice and wild-type littermates that were used as controls; this line was maintained in Regeneron's animal facility in the C57Bl/6NTac genetic background throughout the study.

### **Animal studies**

Mice homozygous for *Slc39a5* loss of function and wild-type littermates were co-housed in a controlled environment (12hr light/dark cycle, 22 ± 1°C, 60-70% humidity) and fed ad-libitum. All studies were performed in both sexes. For HFFD study, ten-week-old mice were fed HFFD diet (46kcal% Fat, 30kcal% Fructose, TestDiet 5WK9) or control diet (TestDiet 58Y2) for 30 weeks. For NASH study, ten-week-old mice were fed NASH diet (40kcal% Fat, 20 kcal% Fructose and 2% Cholesterol, ResearchDiets D09100310) or control diet (ResearchDiets D09100304) for 40 weeks. Both HFFD and NASH diets contain ~34ppm zinc as described in diet spec sheets, and further confirmed by flame atomic absorption spectrometry. *Slc39a5*<sup>-/-</sup>;*Lepr*<sup>-/-</sup> mice and corresponding control mice (*Slc39a5*<sup>+/+</sup>;*Lepr*<sup>-/-</sup>, *Slc39a5*<sup>-/-</sup>;*Lepr*<sup>+/+</sup>, and *Slc39a5*<sup>+/+</sup>;*Lepr*<sup>+/+</sup> mice) were fed a normal chow (LabDiet 5053, containing 87ppm zinc) for 34 weeks. All mice used in this study were housed in pathogen-free environment at Regeneron Pharmaceuticals Inc. animal research facility. Sterile water and show were given ad libitum.

### **Ethics Statement**

All experimental protocols in mice including anesthesia and tissue sampling procedures performed in this study, were approved by Regeneron Pharmaceuticals Inc.

Institutional Animal Care and Use Committee (IACUC) under protocol number 430 and the US Animal Welfare Act.

## **Serum Analysis**

Sera were collected upon an overnight fast (16 hours). The liver and lipid profile were analyzed using Siemens ADVIA Chemistry XPT analyzer which is maintained and operated according to Siemens' guidelines. The liver and lipid profile contains the following reagents: Alanine Aminotransferase (ALT, Siemens REF 03036926), Aspartate Aminotransferase (AST, Siemens REF 07499718), Cholesterol (CHOL, Siemens REF 10376501), Direct HDL Cholesterol (DHDL, Siemens REF 07511947), LDL Cholesterol Direct (DLDL, Siemens REF 09793248), Non-Esterified Fatty Acids (NEFA, Wako 999-34691, 995-34791, 991-34891, 993-35191), Triglycerides (TRIG, Siemens REF 10335892). When mixed with sample, reagents undergo a colorimetric change proportional to the concentration of the specific analyte. The absorbance is then measured with a halogen light source and used to determine concentration. Serum was also collected for ELISA analysis of proinsulin (Merckodia, #10-1232-01) per manufacturer's guidelines. Briefly, samples were incubated with enzyme conjugate at room temperature for two hours and washed. Substrate TMB was added and the reaction was allowed to proceed for 30 minutes at room temperature before stop solution was applied. Optical density was read at 450 nm. Luminex Metabolic panel serum analyses of insulin, c-peptide were performed using a Mouse Metabolic Hormone Magnetic Bead Panel (Millipore, MMHMAG-44K). Experimental protocols for the sample collection, storage, preparation of reagents for immunoassay and immunoassay procedure, followed the specific instructions of the MMHMAG-44K mouse panel supplier. Results were read on a Luminex 200 analyzer with XX software (Xponent/Analyst version 4.2) used for data analysis. Insulin profile was also analyzed in serum collected from mice at fed state.

## **Metal ion quantification**

Assays were performed by the Louisiana Animal Disease Diagnostics Laboratory with an Agilent Technologies 240 FS Atomic Absorption Spectrometer, in flame mode. Serum samples are quantitatively diluted in deionized water and subsequently analyzed.

For the serum samples a Seronorm Trace Elements Serum (L-2) is used as reference. First tissue samples are weighed and digested in nitric acid overnight at 85°C. The following day, the samples are cooled down to room temperature and quantitatively transferred to polystyrene tubes with deionized water, and subsequently analyzed. For all tissue samples, a bovine liver standard reference material (SRM 1577c) from the National Institute of Standards and Technology was used as reference.

### **Liver histology and histopathologic analysis**

Explanted liver samples were fixed in 10% phosphate buffered formalin acetate at 4°C overnight, thoroughly rinsed in phosphate-buffered saline and transferred to 70% ethanol. Histology was performed by HistoWiz Inc. and Histoserv Inc. using standard operating procedures and fully automated workflow. Samples were embedded in paraffin wax and sectioned (5 µm). Prior to staining, slides were deparaffinized in xylene and hydrated with graded alcohols and finally water. Slides were then stained with either hematoxylin & eosin (H&E) or Picrosirius Red. Immunohistochemistry was performed on a Bond Rx autostainer (Leica Biosystems) with heat-induced epitope retrieval. Slides were incubated with primary antibodies F4/80 (Thermo, #14-4801-82), α-smooth muscle actin (Abcam, #ab5694) and Bond Polymer Refine Detection (Leica Biosystems) was used per manufacturer's protocol. Following staining, slides were dehydrated and coverslipped using a TissueTek-Prisma and Coverslipper (Sakura). Whole slide scanning (40x) was performed on an Aperio AT2 (Leica Biosystems). For lipid staining, samples were frozen in O.C.T. compound (Tissue-Tek, #4583) and 5µm thick sections were used. Slides were stained with Oil Red O (ORO) and Mayers hematoxylin and mounted with glycerin jelly. NAFLD scoring was performed by one external pathologist (provided by Histowiz) and one internal pathologist blinded to the samples, according to criteria described by Liang et al<sup>7</sup>. Macrovesicular steatosis (H&E, ORO), hepatocyte hypertrophy (H&E), inflammation (H&E, F4/80) and fibrosis (PSR) were scored ranging from 0 to 3. NAFLD activity score is the sum of steatosis, hepatocyte hypertrophy and inflammation scores. Steatosis-activity-fibrosis score is the sum of NAFLD activity score and fibrosis score.

## **Hepatic Triglyceride assay**

Lipids were extracted from liver samples using Folch method<sup>8</sup> and solubilized as described earlier<sup>9</sup>. The levels of triglyceride were measured using Pointe triglyceride (GPO) reagent set (MedTest Dx, #T7532) and normalized to wet tissue weight.

## **Glucose and insulin tolerance tests**

An oral glucose tolerance test was administered upon an overnight fast (16 hours) with free access to water. Dextrose (Hospira Inc, NDC 0409-4902-34) was administered by oral gavage per 2g/kg of body weight. Blood glucose was evaluated at defined time points (0, 15, 30, 60 and 120 minutes) using AlphaTrak blood glucose monitoring system (Zoetis United States, Parsippany NJ) by sampling blood from the lateral tail vein. Insulin tolerance tests were performed after a 4 hour fast by administering 1.0U/kg of body weight of Humulin R (Eli Lilly, #HI-213) by intra-peritoneal injection. Blood glucose was again evaluated at defined timepoints with the AlphaTrak blood glucose monitoring system by sampling blood from the lateral tail vein.

## **HOMA-IR**

Homeostatic model assessment of insulin resistance (HOMA-IR) indicates level of insulin sensitivity by taking into account the relationship between glucose and insulin. HOMA-IR was calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5.

## **Immunoblotting**

For biochemical analysis, liver samples were harvested and immediately snap frozen in liquid nitrogen. Protein was later extracted using RIPA buffer (Cell signaling technology, #9806) with Halt Protease & Phosphatase Inhibitor Cocktail (ThermoFisher Scientific, #78440). Protein concentration was determined using Pierce TM BCA protein assay kit (Thermo Scientific, #23225). Five micrograms of protein of each sample were



separated in NuPAGE 4-12% Bis-Tris protein gel (Invitrogen, #WG1403BOX), and transferred to nitrocellulose membrane using Trans-Blot® Turbo™ Transfer System (BioRad). The membranes were blocked with 5% non-fat dry milk (BioRad, #9999) for 1 hour at room temperature before incubated with primary antibody overnight at 4°C. Antibodies were purchased from Cell Signaling Technology, phospho-AKT (Ser473, #4060), AKT (#9272), phospho-AMPKα (Thr172, #2535), AMPKα (#5831), phospho-LKB1 (Ser428, #3482), LKB1 (#3047), phospho-ACC (Ser79, #3661), ACC (#3676), FASN (#3189), HRP-linked anti-rabbit IgG (#7074) and HRP-linked anti-mouse IgG (#7076). Antibodies for G6PC (Invitrogen, #PA5-42541), SLC39A5 and β-actin (Sigma #5441) were used. For detection of SLC39A5 protein, liver samples were immunoprecipitated using Pierce Protein A/G Magnetic Beads and anti-SLC39A5 antibodies (Invitrogen, #88803, 42522), and eluted for western blot analysis. All membranes were washed before incubation with HRP-linked secondary antibody for one hour at room temperature. Blots were developed using SuperSignal West Femto Substrate (ThermoFisher Scientific, #34095). Signals were captured using G:Box Mini 9 (Syngene). Densitometry analysis of immunoblots were performed using ImageJ.

### Gene expression analysis

Tissues were preserved in RNAlater solution immediately following harvest. Total RNA was purified using MagMAX™-96 for Microarrays Total RNA Isolation Kit (Invitrogen, #AM1839) according to manufacturer's specifications. Genomic DNA was removed using MagMAX™Turbo™DNase Buffer and TURBO DNase from the MagMAX kit listed above. mRNA (Up to 2.5ug) was reverse-transcribed into cDNA using SuperScript® VILO™ Master Mix (Invitrogen, #11755500). cDNA was diluted to 0.5-5ng/uL. 2.5-25ng cDNA input was amplified with the SensiFAST Hi-ROX MasterMix (BIOLINE, #CSA-01113) using the ABI 7900HT Sequence Detection System (Applied Biosystems). The sequences of primers are as follows: *Slc39a5* (F 5'-CGAGCCTAGACCTCTTCCA- 3', R 5'-GGGAGCCATTCAGACAATCC-3'), *Mt1* (F 5'-CAAGTGACCTCCTGCAAGAAG-3', R 5'-CACAGCCCTGGGCACATTT-3'), *Mt2* (F 5'-GACCCCAACTGCTCCTGTG-3', R 5'-CTTGCAGGAAGTACATTTGCATTG-3'), *G6pc* (F

5'-GGTCGTGGCTGGAGTCTTG-3', R 5'-CCGGAGGCTGGCATTGTAG-3') and *Fasn* (Thermofisher Scientific #Mm00662319\_m1).

### **Human primary hepatocyte culture**

Human Plateable Hepatocytes were purchased from Invitrogen (#HMCP5, Lot No HPP1881027 and HPP1878738) and used according to manufacturer protocol. These Hepatocytes are a pooled population of primary hepatocytes produced by combining cells from 5 individual donors. All reagents and materials were purchased from Invitrogen. Briefly, cryopreserved hepatocytes were thawed in hepatocyte thawing medium (#CM7500). Hepatocytes were centrifuged and resuspend in plating medium, Williams' Medium E (#A1217601) with hepatocyte plating supplement (#CM3000). Hepatocytes were directly plated in collagen I coated 24-well plate (#A1142802). After 6 hours incubation, media were replaced with incubation medium, Williams' Medium E with hepatocyte maintenance supplement (#CM4000). Next day, hepatocytes were treated with ZnCl<sub>2</sub> or MgCl<sub>2</sub> at the concentrations of 100, 200 and 400uM in incubation medium for four hours. Magnesium was used as a negative control, given that zinc and magnesium have opposite roles in the activation of protein tyrosine phosphatase 1B<sup>10</sup>. In addition, Okadaic acid (OA) and Metformin (Met) were used as positive controls. OA is an inhibitor of the serine/threonine protein phosphatases (PP2A and PP1), resulting in an elevation of p.AMPK $\alpha$  Thr172 and p.AKT Ser473 levels in hepatocytes<sup>11, 12</sup>. Metformin is an antidiabetic drug that induces phosphorylation of AMPK in liver<sup>13</sup>. Protein lysates were collected using RIPA buffer with Halt Protease & Phosphatase Inhibitor and subjected for immunoblotting. Cell Viability assay was performed using CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) assay (Promega, #G3580) per manufacturer's protocol.

### **Generation of Slc39a5 plasmids**

Mouse *Slc39a5* ORF sequence was cloned into pIRES2 DsRed-Express2 vector (Clontech, #PT4079-5). Constructs of SLC39A5 variants were generated using site-

directed mutagenesis method, with oligos for Y47X (F 5'CCCATCTCGCCCTACAGGCCAAACAGCTG-3', R 5-CAGCTGTTTGGCCTGTAGG GCGAGAATGGG-3'), R311X (F 5'-GGCCTGAGCCCTCAGTGCCGCAAAGC-3', R 5'-GCTTTTGCGGCACTGAGGGCTCAGGCC-3'), R322X (F 5'-GTTTCGAGATTCCTTCAT TTTGCGCCTGCAGCATCT-3', R 5'-AGATGCTGCAGGCGAAAATGAAGGAATCTCGAA AC-3') and M304T (F 5'-AAAGCCCCAGCGTGTCTCCAGCACAAAGAGCA-3', R 5'-TGCTCTTTGTGCTGGAGAACACGCTGGGGCTTT-3'). Mutagenesis was confirmed by Sanger sequencing.

### **Membrane localization of SLC39A5 using flow cytometry:**

HEK293 cells were plated on a 10cm dish at a density of 25,000 cells/cm<sup>2</sup> and incubated at 37°C at 5% CO<sub>2</sub> overnight in high glucose DMEM with 10% FBS and 1% Penn Strep (Gibco, #11965092). Cells were transfected the next day with 10ug plasmid DNA using Xtremegene HP (Roche, #06366244001) in Opti-MEM (Gibco, #31985-070). Transfection complexes were incubated at room temperature for 20 minutes and added dropwise to the cells. Cells were incubated at 37°C. A single media change was performed after 48 hours using Gibco DMEM high glucose and no other supplements. Following 24 hours of incubation at 37°C cells were washed with DPBS and dissociated with Cell dissociation Buffer (Gibco, #13151-014). Cells were resuspended in 0.5% BSA (Sigma, #A7030) in DPBS and centrifuged at 200g for 5 minutes. BD Biosciences CytoFix Fixation buffer (BD, #554655) was added to each sample and incubated at 4C for 20 minutes. Cells were washed and stained with either anti-human SLC39A5 (Sigma, #SAB1408465) or isotype control followed by secondary Alexa 488 (ThermoFisher, #A28175). Cells were washed and re-suspended in 0.5% BSA in DPBS. All samples were analyzed on a BD FACS Cantoll.

### **MRE-luc assay**

HEK293 cells were plated in 96-well plate at a density of 22,000 cells/well. Cells were transfected with MRE-luc (Promega pGL4.40), hRluc (Promega pGL4.75) and *Slc39a5* constructs with XtremeGene HP (Roche) transfection reagent. MRE-binding transcription factor 1 (MTF1) is responsible for expression of metallothioneins (MTs) in

response to zinc. After 24 hours, medium was changed with 0.5% charcoal stripped FBS in DMEM + Glutamax (Life Technologies, #10569010). Twenty-four hours later, the cultures were exposed to  $Zn^{2+}$  for 6 hours. Luciferase activity was measured using Dual-Glo luciferase assay system (Promega, #E2920). Results were expressed as the relation of firefly luciferase activity to Renilla luciferase activity.

### **Live staining & Immunofluorescence**

HEK293 cells were plated on Ibidi chamber slides (Ibidi, #80427) coated with 100 $\mu$ g/mL of poly-L-lysine. Live cells staining was performed by diluting primary antibody (Polyclonal anti-SLC39A5, Sigma SAB1408465, 1:100) in cold culture medium and incubated with the cells for 2 hours at 4°C. Slides were washed with cold PBS 3x 10 minutes at 4°C with gentle shaking. Cells were fixed with 2% paraformaldehyde at room temperature for 5 minutes and washed with PBS. Wheat germ agglutinin in HBSS was added to cells for 10 minutes at room temperature and then blocked with 5% goat serum. Secondary antibody was applied for 45 minutes at room temperature. Cells were washed and mounted with ProLong diamond antifade solution and imaged using Zeiss AxioObserver LSM880.

### **Hepatic $\beta$ -hydroxybutyrate assay**

$\beta$ -OHB (Sigma, #MAK041) was measured in mouse liver tissue by colorimetric assays per manufacturer's guidelines. Briefly, liver samples (10mg/sample) were homogenized in 4 volumes of cold  $\beta$ -OHB assay buffer. Samples were centrifuged at 13,000g for 10 minutes at 4°C and supernatant was used for analyses. Concentration is determined by a coupled enzyme reaction which results in a colorimetric (450nm) product proportional to the  $\beta$ -OHB present.

### **Protein Phosphatase Assay**

Cultured hepatocyte lysates and tissue homogenates were prepared by Lysis Reagent (Invitrogen, #M10510) with protease inhibitor cocktail (Sigma, #P8340). Protein lysates were centrifuged at 4°C for 15 minutes and protein concentration was determined using Pierce TM BCA protein assay kit. Phosphatase activity was measured using

RediPlate™ 96 EnzChek™ Tyrosine Phosphatase and Serine/Threonine Phosphatase Assay Kit (Invitrogen, #R22067, R33700) per manufacturer's instructions. Samples were incubated in RediPlate for 60 mins before reading by fluorescence microplate with excitation/emission at 358/455nm (Spectramax M4, Molecular Devices).

### **Superoxide Dismutase (SOD) assay**

SOD activity was measured in mouse liver tissues using SOD activity kit (ENZO, #ADI-900-157). Briefly, liver samples (30mg/sample) were homogenized in 10 volumes of cell extraction buffer. Samples were centrifuged at 10,000g for 10 minutes at 4°C and supernatant was used for analysis. Protein concentration was determined by Pierce™ BCA protein assay kit (Thermo Scientific, #23225). Samples were diluted to 50ug/25ul for assay, according to protocol.

### **Statistical analysis**

Results are shown as box plots with individual values. Statistical analysis was performed using GraphPad Prism 8 software. Analysis for *Slc39a5*<sup>-/-</sup>; *Lepr*<sup>-/-</sup> mice and corresponding control mice was performed using one-way ANOVA, followed by post hoc Tukey's tests. Analysis for HFFD and NASH mouse studies was performed using two-way ANOVA, followed by post hoc Tukey's tests. Statistical significance reported when  $p < 0.05$ . Sample sizes, statistical test and significance are described in each figure legend.

### **References**

- [1] Eastwood SV, Mathur R, Atkinson M, Brophy S, Sudlow C, Flaig R, et al. Algorithms for the Capture and Adjudication of Prevalent and Incident Diabetes in UK Biobank. *PLoS One* 2016;11:e0162388.
- [2] Lotta LA, Wittemans LBL, Zuber V, Stewart ID, Sharp SJ, Luan J, et al. Association of Genetic Variants Related to Gluteofemoral vs Abdominal Fat Distribution With Type 2 Diabetes, Coronary Disease, and Cardiovascular Risk Factors. *JAMA* 2018;320:2553-2563.
- [3] Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design and feasibility. *J Intern Med* 1993;233:45-51.
- [4] Mbatchou J, Barnard L, Backman J, Marcketta A, Kosmicki JA, Ziyatdinov A, et al. Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet* 2021.

- [5] Poueymirou WT, Auerbach W, Frendewey D, Hickey JF, Escaravage JM, Esau L, et al. F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses. *Nat Biotechnol* 2007;25:91-99.
- [6] Valenzuela DM, Murphy AJ, Frendewey D, Gale NW, Economides AN, Auerbach W, et al. High-throughput engineering of the mouse genome coupled with high-resolution expression analysis. *Nat Biotechnol* 2003;21:652-659.
- [7] Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. *PLoS One* 2014;9:e115922.
- [8] Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem* 1957;226:497-509.
- [9] Carr TP, Andresen CJ, Rudel LL. Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. *Clin Biochem* 1993;26:39-42.
- [10] Bellomo E, Abro A, Hogstrand C, Maret W, Domene C. Role of Zinc and Magnesium Ions in the Modulation of Phosphoryl Transfer in Protein Tyrosine Phosphatase 1B. *J Am Chem Soc* 2018;140:4446-4454.
- [11] Samari HR, Moller MT, Holden L, Asmyhr T, Seglen PO. Stimulation of hepatocytic AMP-activated protein kinase by okadaic acid and other autophagy-suppressive toxins. *Biochem J* 2005;386:237-244.
- [12] Galbo T, Olsen GS, Quistorff B, Nishimura E. Free fatty acid-induced PP2A hyperactivity selectively impairs hepatic insulin action on glucose metabolism. *PLoS One* 2011;6:e27424.
- [13] Howell JJ, Hellberg K, Turner M, Talbott G, Kolar MJ, Ross DS, et al. Metformin Inhibits Hepatic mTORC1 Signaling via Dose-Dependent Mechanisms Involving AMPK and the TSC Complex. *Cell Metab* 2017;25:463-471.